
<html lang="en"     class="pb-page"  data-request-id="4b4a7a32-0782-4fa2-ae32-131c5bae556f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm2017094;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2012.55.issue-10;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions" /></meta><meta name="dc.Creator" content="Robert A.  Heald" /></meta><meta name="dc.Creator" content="Philip  Jackson" /></meta><meta name="dc.Creator" content="Pascal  Savy" /></meta><meta name="dc.Creator" content="Mark  Jones" /></meta><meta name="dc.Creator" content="Emanuela  Gancia" /></meta><meta name="dc.Creator" content="Brenda  Burton" /></meta><meta name="dc.Creator" content="Richard  Newman" /></meta><meta name="dc.Creator" content="Jason  Boggs" /></meta><meta name="dc.Creator" content="Emily  Chan" /></meta><meta name="dc.Creator" content="Jocelyn  Chan" /></meta><meta name="dc.Creator" content="Edna  Choo" /></meta><meta name="dc.Creator" content="Mark  Merchant" /></meta><meta name="dc.Creator" content="Patrick  Rudewicz" /></meta><meta name="dc.Creator" content="Mark  Ultsch" /></meta><meta name="dc.Creator" content="Christian  Wiesmann" /></meta><meta name="dc.Creator" content="Qin  Yue" /></meta><meta name="dc.Creator" content="Marcia  Belvin" /></meta><meta name="dc.Creator" content="Steve  Price" /></meta><meta name="dc.Description" content="Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, ..." /></meta><meta name="Description" content="Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 3, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm2017094" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm2017094" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm2017094" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm2017094" /></link>
        
    
    

<title>Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm2017094" /></meta><meta property="og:title" content="Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0001.jpeg" /></meta><meta property="og:description" content="Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm2017094"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm2017094">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm2017094&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm2017094&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm2017094&amp;href=/doi/10.1021/jm2017094" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4594-4604</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201550q" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300030r" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Heald">Robert A. Heald</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Jackson">Philip Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pascal++Savy">Pascal Savy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Jones">Mark Jones</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emanuela++Gancia">Emanuela Gancia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brenda++Burton">Brenda Burton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Newman">Richard Newman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Boggs">Jason Boggs</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Chan">Emily Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jocelyn++Chan">Jocelyn Chan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edna++Choo">Edna Choo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Merchant">Mark Merchant</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Rudewicz">Patrick Rudewicz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Ultsch">Mark Ultsch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Wiesmann">Christian Wiesmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Yue">Qin Yue</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcia++Belvin">Marcia Belvin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Price">Steve Price</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Argenta, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +44 (0) 1279 645623. Fax: +44 (0) 1279 645646. E-mail: <a href="/cdn-cgi/l/email-protection#d1a3beb3b4a3a5ffb9b4b0bdb591b6bda1b6ffb2bebc"><span class="__cf_email__" data-cfemail="3d4f525f584f491355585c51597d5a514d5a135e5250">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm2017094&amp;href=/doi/10.1021%2Fjm2017094" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4594â4604</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 16, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 December 2011</li><li><span class="item_label"><b>Published</b> online</span>3 May 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm2017094" title="DOI URL">https://doi.org/10.1021/jm2017094</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4594%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRobert%2BA.%2BHeald%252C%2BPhilip%2BJackson%252C%2BPascal%2BSavy%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D10%26contentID%3Djm2017094%26title%3DDiscovery%2Bof%2BNovel%2BAllosteric%2BMitogen-Activated%2BProtein%2BKinase%2BKinase%2B%2528MEK%2529%2B1%252C2%2BInhibitors%2BPossessing%2BBidentate%2BSer212%2BInteractions%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4604%26publicationDate%3DMay%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm2017094"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3693</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm2017094" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Heald&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Jackson&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;Savy&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Jones&quot;},{&quot;first_name&quot;:&quot;Emanuela&quot;,&quot;last_name&quot;:&quot;Gancia&quot;},{&quot;first_name&quot;:&quot;Brenda&quot;,&quot;last_name&quot;:&quot;Burton&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Newman&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Boggs&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Jocelyn&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Edna&quot;,&quot;last_name&quot;:&quot;Choo&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Merchant&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Rudewicz&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Ultsch&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Wiesmann&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Yue&quot;},{&quot;first_name&quot;:&quot;Marcia&quot;,&quot;last_name&quot;:&quot;Belvin&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Price&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;4594-4604&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm2017094&quot;},&quot;abstract&quot;:&quot;Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, 1 (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2017094&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2017094" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2017094&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2017094" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm2017094&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2017094" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm2017094&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm2017094&amp;href=/doi/10.1021/jm2017094" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm2017094" /></input><a href="/doi/pdf/10.1021/jm2017094" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm2017094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm2017094%26sid%3Dliteratum%253Aachs%26pmid%3D22506516%26genre%3Darticle%26aulast%3DHeald%26date%3D2012%26atitle%3DDiscovery%2Bof%2BNovel%2BAllosteric%2BMitogen-Activated%2BProtein%2BKinase%2BKinase%2B%2528MEK%2529%2B1%252C2%2BInhibitors%2BPossessing%2BBidentate%2BSer212%2BInteractions%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D10%26spage%3D4594%26epage%3D4604%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jmcmar.2012.55.issue-10/production/jmcmar.2012.55.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Using structure-based design, two novel series of highly potent biaryl amine mitogen-activated protein kinase kinase (MEK) inhibitors have been discovered. These series contain an H-bond acceptor, in a shifted position compared with previously disclosed compounds, and an adjacent H-bond donor, resulting in a bidentate interaction with the Ser212 residue of MEK1. The most potent compound identified, <b>1</b> (G-894), is orally active in in vivo pharmacodynamic and tumor xenograft models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span></span>Â Accession Codes</h4><p class="last">The coordinates for the crystal structures of <b>1</b> and <b>3</b> with MEK1 have been deposited with the RCSB Protein Data Bank under the accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V04">3V04</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VO1">3VO1</a>, respectively.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Ras-Raf-MEK-ERK mitogen-activated protein kinase signaling pathway is one of the most promising targets for a new wave of molecularly targeted antitumor agents.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Constitutive activation of the extracellular regulated kinase (ERK) cascade, through oncogenic forms of Ras and mutations in B-Raf, has been observed in lung, colon, pancreas, kidney, and ovary primary human tumor samples.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Similarly, hyperactivity by upstream receptor tyrosine kinases such as human epidermal growth factor receptor 2 (HER2) leads to increased signaling through the ERK pathway.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Research efforts in recent years have uncovered a variety of inhibitors of Raf, MEK, and ERK kinases as potential antitumor agents.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">MEK is a crucial node in the ERK MAPK pathway: the only known downstream targets of MEK1/2 are ERK1/2. This has led to particularly intense efforts to discover inhibitors of this target, and there are now 13 MEK inhibitors at some stage of clinical evaluation for the treatment of cancer, with two others having been withdrawn.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> The first MEK inhibitors to progress past phase I clinical trials were <b>2</b> (AZD6244/Selumetinib, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>)<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> and PD325901,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> both of which were progressed to phase II studies as single agents for the treatment of a variety of tumor types. Studies with <b>2</b> as a single agent and in combination with other antitumor agents are continuing.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The most advanced MEK inhibitor is GSK1120212,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> which began a phase III trial in BRAF V600E positive melanoma patients in late 2010.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of designed analogue <b>1</b> with <b>2</b>, <b>3</b>, and <b>4</b>. âAâ and âBâ rings of <b>2</b> are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although MEK inhibition alone is expected to provide significant therapeutic benefit, there is considerable evidence for synergistic combination with other targeted agents. For example, concerted MEK and PI3K inhibition provides synergistic inhibition of tumor growth in basal-like breast cancer models.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Additionally, it has been demonstrated that in K-Ras mutant cell lines, Raf inhibition primes wild-type Raf to activate the Raf-MEK-ERK pathway, providing a clear rational for combination therapy with MEK inhibitors.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Allosteric MEK1/MEK2 inhibitors<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> are particularly discriminating kinase inhibitors. These compounds form a tertiary complex with the MEK enzyme and the ATP binding site and are thus uncompetitive.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> The binding site for so-called type III kinase inhibitors is proximal to ATP and results in high specificity for the target enzyme. It has been postulated that this allosteric âMEK pocketâ may be present in other kinases.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Examination of structural features of inhibitors disclosed in the patent literature reveals that the allosteric binding pocket of MEK1 is highly discriminating in its affinity for drug molecules, resulting in low structural diversity.<a onclick="showRef(event, 'ref15 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref19">(15, 19)</a> The structures of seven compounds that have entered the clinic have been disclosed: all are biaryl amines, by far the most common class of MEK inhibitor. The potency of these inhibitors is postulated to depend on three pharmacophoric elements (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The first of these is a âB-ringâ, which occupies the lipophilic pocket formed by Leu118, Ile126, Val127, Ile141, Met143, Phe129, Phe209, and Val211, an important feature of which is para-substitution with a lipophilic polarizable atom or group capable of forming an interaction with the carbonyl of Val127. Where this atom is a halogen, the interaction is termed a halogen bond.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> The second feature is a polar group which can interact with the terminal phosphate of ATP and Lys97, typically a hydroxamate, but sometimes an amide, reverse sulfonamide, or sulfonyl urea.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The third feature is an H-bond acceptor, which is suitably juxtaposed to Ser212. The strength of this H-bond acceptor<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and position relative to the aniline and hydroxamate are determined by the âA-ringâ to which these moieties are attached. It has been proposed that increasing the strength of the Ser212/H-bond acceptor interaction results in greater tolerance in the other pharmacophoric elements.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The key interactions of biarylaniline MEK inhibitors: crystal structure of MEK1 in complex with ATP (green) and PD318088 (orange) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1S9J">1S9J</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our search for additional MEK inhibitors, we utilized a computer-aided drug design (CADD) driven approach leveraging key information from the X-ray crystal structure (2.7 Ã resolution) of <b>3</b> (G-925, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), a compound from our first series of novel inhibitors<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> which was optimized to give the orally efficacious analogue <b>4</b> (G-573).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> From 2-D overlay of <b>2</b> and <b>3</b>, it was noticed that the two A ring systems position the H-bond acceptor differently. Additionally, it was realized that for a 6,5-heterobicyclic system fusion of the five-membered ring toward the B-ring, in the opposite sense to <b>2</b>, together with movement of the acceptor round one position, placed the key pharmocophoric elements described above in remarkably similar position to <b>3</b>. An H-bond donor was added next to the acceptor, as it was postulated that this position would be proximal to the carbonyl of Ser212 resulting in the design of <b>1</b> (G-894, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). This designed compound is fundamentally different to all six-membered aryl and 6,5-fused biaryl amine MEK inhibitors disclosed in the literature in that the putative H-bond acceptor is not positioned on the six-membered ring meta to the aniline. Modeling of the indazole <b>1</b> in the <b>3</b>/MEK1 protein structure was performed using docking (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, A) and manual placement (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, B), as docking algorithms underestimate the iodine Val127 interaction. The docked pose shows bidentate Ser212 interaction, but the aniline â¼1.3 Ã out of the lipophilic pocket compared with <b>3</b>. In the manual overlay, the indazole acceptor was still appropriately positioned near Ser212, with the NH donor shifted slightly from the Ser212 carbonyl to a distance of 3.0 Ã. Although neither pose of <b>1</b> was ideal, the protein movement required to enable all desired contacts is minimal.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Overlay between the docked pose of <b>1</b> (orange) and the crystal structure of <b>3</b> (cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V01">3V01</a>). (B) Overlay between <b>1</b> manually adjusted in the binding site (orange) and the crystal structure of <b>3</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It should be noted that it is not possible to achieve a formal bidentate Ser212 interaction using monoaryl or 6,5-fused biaryl MEK inhibitor scaffolds which have been previously disclosed. The possibility of identifying a MEK inhibitor making such a bidentate interaction with Ser212, which could lead to increased affinity, led us to target the synthesis of <b>1</b>.</div><div class="NLM_p">The desired 4-phenylamino-5-carboxylic acid core was synthesized following the route outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Commercially available 2-bromo-4-fluorobenzoic acid was converted to the <i>tert</i>-butyl ester <b>5</b> under standard conditions. Regiospecific metalation with LDA followed by DMF quench gave aldehyde <b>6</b>. Cyclization of the <i>ortho</i>-fluoro aldehyde <b>6</b> to indazole <b>7</b> and subsequent reaction with boc-anhydride provided the appropriately substituted and protected indazole core <b>8</b>. Palladium-catalyzed amination with 2-fluoro-4-trimethylsilyl aniline using xantphos as the ligand<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> gave anilino ester <b>9</b>. Regiospecific iodination, directed by the trimethylsilyl group, followed by simultaneous boc-deprotection and ester hydrolysis, provided 4-(2-fluoro-4-iodo-phenylamino)-1<i>H</i>-indazole-5-carboxylic acid <b>10a</b>. Installation of the hydroxamate side-chain could then be achieved via a coupling reaction with vinyl hydroxylamine <b>11a</b> followed by acid-mediated deprotection. Bromo analogue <b>12</b> was prepared similarly from intermediate <b>9</b> using NBS rather than iodine monochloride for the halogentation step. Diol analogue <b>13</b> was also prepared from acid intermediate <b>10a</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Indazole Analogues <b>1</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (COCl)<sub>2</sub>, DMF, DCM, (ii) tBuOH, pyridine, DCM; (b) (i) LDA, THF, (ii) DMF; (c) N<sub>2</sub>H<sub>4</sub>Â·H<sub>2</sub>O DME, 90 Â°C; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM; (e) Pd<sub>2</sub>dba<sub>3</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, toluene, 90 Â°C; (f) (i) ICl, DCM or NBS, DCM, (ii) TFA, DCM; (g) EDCI, DIPEA, HOBt, DMF; (h) MeOH, HCl.</p></p></figure><div class="NLM_p">In a biochemical homogeneous time-resolved fluorescence (HTRF) assay, <b>1</b> was found to be â¼2.5-fold more potent than <b>4</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), demonstrating that this designed analogue is a potent inhibitor of MEK. Potency was further assessed in HCT116 (K-Ras mutant human colorectal carcinoma cell line) and A375 (BRAF V600E mutant human melanoma cell line) cell lines, determining both the inhibition of ERK phosphorylation and cell proliferation. In these assays, <b>1</b> is consistently â¼10-fold more potent than <b>4</b>. Bromo analogue <b>12</b> is less potent than <b>1</b>, as would be expected by reduction in strength of the Val127 halogen bond. However, <b>12</b> is equipotent with <b>4</b> in cellular assays, again demonstrating the excellent potency facilitated by the indazole scaffold. Results for <b>4</b> and <b>13</b> show a direct comparison between the azabenzofuran and indazole scaffolds. The indazole <b>13</b> is marginally more potent in the HTRF assay, equipotent in A375 cells, but much more potent in HCT116 cellular assays. The improved potency in cellular but not biochemical assays of the indazole compared with azabenzofurans is intriguing. As all of these compounds are uncompetitive with respect to ATP, it is understandable that cellular potency is greater than biochemical potency due to high intracellular concentrations of ATP. As the biochemical assay used a constitutively activated kinase construct, cellular data were taken to be more indicative of true potency. Differences in proliferation values between the two cell lines used are most likely due to differential sensitivity, as the shift between A375 and HCT116 cell lines is consistently 8â10-fold. <b>1</b> shows high specificity for MEK inhibition with <40% inhibition at 1 Î¼M against a panel of 100 kinases (Invitrogen SelectScreen, see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), indicating that inclusion of the indazole was not leading to promiscuous kinase hinge-binding.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activity of Indazole Analogues <b>1</b>, <b>12</b>, and <b>13</b> Compared with Azabenzofurans <b>3</b> and <b>4</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">P-ERK EC<sub>50</sub>(nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">cell proliferation EC<sub>50</sub>(nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MEK HTRF IC<sub>50</sub>(nM)</th><th class="colsep0 rowsep0" align="center" char=".">HCT116</th><th class="colsep0 rowsep0" align="center" char=".">A375</th><th class="colsep0 rowsep0" align="center" char=".">HCT116</th><th class="colsep0 rowsep0" align="center" char=".">A375</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">34.0</td><td class="colsep0 rowsep0" align="char" char=".">314</td><td class="colsep0 rowsep0" align="char" char=".">264</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">175</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">193</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr></tbody></table></div></div><div class="NLM_p">An X-ray cocrystal structure (2.7 Ã resolution) of <b>1</b> with MEK1 and ATP was obtained which confirmed the allosteric mode of binding and bidentate interaction with Ser212 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, modeled hydrogen atoms shown for clarity) and a structure consistent with the manual overlay shown above (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, panel B). As expected, the iodo-aniline is positioned in the lipophilic pocket with the iodine atom â¼3.3 Ã from the carbonyl of Val127, an appropriate distance for formation of a halogen bond. With the aniline positioned ideally for lipophilic contacts and halogen bond, the indazole is able to make a donorâacceptor interaction with Ser212. The interatom distance for both the H-bonding atom pairs is 2.58 Ã with angles of 134Â° and 142Â° for the indazole N Ser NH and indazole NH Ser CO interactions. Comparison with the crystal structure of <b>3</b> shows a small but significant induced-fit movement of Ser212 (when compared with the highly conserved positions of other residues in the pocket) which allows the three pharmacophoric elements to interact as desired: a shift of 0.48 Ã is observed for the carbonyl oxygen. The shift in Ser212 to accommodate the donorâacceptor pair of <b>1</b> indicates that the postulated bidentate interaction exists and most adequately explains the potency of this compound.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>1</b> in complex with MEK1 (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V04">3V04</a>); modeled hydrogens shown for clarity. For comparison, the crystal structure of MEK1 in complex with <b>3</b> is also shown (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When dosed in rats, the rate of clearance of <b>1</b> was found to be moderate â¼2/3 liver blood flow (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) and oral exposure and bioavailability were low. Similar results were found in mice where clearance was approximately equal to liver blood flow and oral exposure (AUC) was low. Low oral bioavailability in rat was attributed to high liver extraction ratio and poor solubility (solubility 0.08 mg/mL (pH 6.5), 0.18 mg/mL (FASSIF); measured MDCK permeability was moderate to high with low efflux (A:B 9.9 B:A 13.8 Ã 10<sup>â6</sup> cm/s; ratio: 1.4). Analysis of plasma samples following oral dosing in rats showed that glucoronidation and cleavage of the hydroxamate to acid were the major routes of metabolism (see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>). Bioavailability in mouse at 25 mg/kg was higher perhaps due to saturation of clearance mechanisms. The bromo analogue <b>12</b> was found to have higher clearance in rat than the iodo analogue despite lower lipophilicity, and bioavailability was found to be low. Diol hydroxamate <b>13</b> was not progressed into PK as it exhibited low MDCK cell permeability (A:B 2.0, B:A 7.1 Ã 10<sup>â6</sup> cm/s efflux ratio 3.5). The azabenzofuran <b>4</b> has much lower clearance and higher oral exposure than <b>1</b> in mice.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Rodent PK Data for <b>1</b>, <b>4</b>, and <b>12</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">PPB<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)/route</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>(mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a>(h)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a>(L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a> (Î¼MÂ·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t2fn6" aria-label="f">f</a>(%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">96.1</td><td class="colsep0 rowsep0" align="left">1/IV</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">1.01</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">5/PO<sub>(solution)</sub></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.06</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">97.0</td><td class="colsep0 rowsep0" align="left">1/IV</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">25/PO<sub>(suspension)</sub></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.96</td><td class="colsep0 rowsep0" align="char" char=".">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">98.4</td><td class="colsep0 rowsep0" align="left">1/IV</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">4.42</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">25/PO<sub>(suspension)</sub></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">192</td><td class="colsep0 rowsep0" align="char" char=".">173</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">96.5</td><td class="colsep0 rowsep0" align="left">1/IV</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">5/PO<sub>(solution)</sub></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.29</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Clearance.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Half-life.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Area under the curve.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Bioavailability. For oral studies, MCT was used for suspension dosing and 60% PEG 400 for solution.</p></div></div></div><div class="NLM_p">Despite low oral exposure in rodents. the high potency of <b>1</b> in cellular assays warranted further investigation of this compound in an efficacy study. Gratifyingly, when dosed orally in nude HCT-116 tumor-bearing mice, <b>1</b> exhibited substantially greater efficacy at 5 mg/kg than <b>4</b> at the same dose (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), with tumor growth inhibition (TGI) approaching stasis (94%). The 5 mg/kg dose was well tolerated with no loss of body weight compared with vehicle (data not shown). At the 25 and 75 mg/kg doses, 5 and 10 out of 10 partial responses were observed but â¼10% loss of body weight was noted at the higher dose. This improved efficacy compared with <b>4</b> can be largely attributed to increased potency. The free fraction for <b>1</b> in mice is â¼2-fold higher than for <b>4</b>, which is perhaps within the error of the experiment, whereas the exposure of 1 is â¼10-fold higher. Efficacy was found to correlate with inhibition of ERK phosphorylation in a separate pharmacodynamic experiment: a single dose of <b>1</b> at 25 mg/kg led to maximal inhibition of pERK (â¼70% of control values) through 8 h (see <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy in HCT116 colorectal xenograft model. Mice were randomized and treated with vehicle or <b>1</b> at 5, 25, and 75 mg/kg or <b>4</b> at 5 mg/kg, orally (PO) every day (QD) for 3 weeks. \ = death or euthanasia: 2 animals in the vehicle treated group had tumor volume >2000 mm<sup>3</sup>; animals euthanized in the compound treated groups had body weight loss >20%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an attempt to optimize the PK/potency balance, a number of analogues were prepared from acid intermediate <b>10a</b> that investigated variation of the hydroxamate group (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). These analogues were assessed using in vitro or in vivo experiments as appropriate. Cyclopropylmethyl (<b>14</b>) and ethyl (<b>15</b>) hydroxamate analogues were found to be significantly less potent than <b>1</b>, and both showed no oral exposure when dosed at 5 mg/kg in rats (data not shown). Replacement of the hydroxamate with amides was not tolerated: <b>16</b> exhibited an IC<sub>50</sub> of >10 Î¼M in the HTRF assay, and the azetidinol analogue <b>17</b> possessed very weak activity. In general, it appears that the indazole scaffold, despite enabling a bidentate donorâacceptor interaction with Ser212, is less tolerant of changes to the hydroxamate compared with previously disclosed pyridone monocyclic inhibitors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This is perhaps due to less flexibility in positioning of the donorâacceptor element of the indazole compared with the monodentate pyridone.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activity Data for Further Indazole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0010.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Owing to the difficulty in balancing potency, metabolic stability, and oral bioavailability in the indazole series, our thoughts turned to other scaffolds that take advantage of our discovery of a bidentate Ser212 interaction and movement in the position of the H-bond acceptor. It has been postulated that the CH of some five-membered heterocycles can act as a weak H-bond donor.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Additionally, it is likely that our earlier azabenzofuran template is positioned appropriately to make a similar interaction. Replacing the fused pyrazole ring of <b>1</b> with an isothiazole would provide a system able to make a CâHÂ·Â·Â·O donorâacceptor interaction with Ser212 with reduced polarity. It was considered that the lower energy of H-bond interaction may be compensated for by a reduced desolvation penalty compared with the indazole.</div><div class="NLM_p">The synthesis of targeted analogues <b>18</b> and <b>19</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) depended on preparation of a benzoisothiazole with an unprecedented substitution pattern. The required intermediate, tetra-substituted derivative <b>22</b>, was prepared in two steps from ester <b>20</b> via radical bromination followed by oxidation with trimethylamine oxide and DMSO. Regiospecific S<sub>N</sub>Ar displacement at the 3-position with phenylmethanethiol was achieved using potassium <i>tert</i>-butoxide at low temperature to furnish the desired compound <b>23</b>. The isothiazole ring was formed following a two-step procedure,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> providing the 6,7-disubstituted benzoisothiazole scaffold <b>24</b>. The 2-fluoro-4-iodoaniline was introduced through S<sub>N</sub>Ar displacement of the remaining fluorine atom using LHMDS at low temperature, giving the aniline ester <b>25</b>. Subsequent steps were carried out as for the indazole analogues.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route to Benzoisothiazole Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Boc<sub>2</sub>O, DMAP, tBuOH, 45 Â°C; (b) NBS, AIBN, CCl<sub>4</sub>, reflux; (c) trimethylamine oxide, DCM, DMSO, rt; (d) BnSH, tBuOK, THF, â30 Â°C; (e) (i) SOCl<sub>2</sub>, DCM, rt, (ii) NH<sub>3</sub>, MeOH, THF, rt; (f) LHMDS, THF, â78 Â°C; (g) TFA, DCM, rt; (h) RONH<sub>2</sub>, EDCI, HOBt, DIPEA, THF, rt; (i) HCl, MeOH, rt.</p></p></figure><div class="NLM_p">Pleasingly, hydroxyethyl hydroxamate analogue <b>18</b> showed excellent potency in all assays and is only â¼2â3-fold less potent than the direct indazole analogue <b>1</b> in P-ERK and cell proliferation assays (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). These data prove that a formal H-bond donor on this novel 6,5-fused scaffold is not necessary for excellent potency. Diol analogue <b>19</b> is 2-fold less potent than indazole analogue <b>13</b> in the HTC116 cell proliferation assay and equipotent in A375 cells.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activity Data for Benzoisothiazole Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">P-ERK EC<sub>50</sub>(nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">cell proliferation EC<sub>50</sub>(nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MEK HTRF IC<sub>50</sub>(nM)</th><th class="colsep0 rowsep0" align="center" char=".">HCT116</th><th class="colsep0 rowsep0" align="center" char=".">A375</th><th class="colsep0 rowsep0" align="center" char=".">HCT116</th><th class="colsep0 rowsep0" align="center" char=".">A375</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr></tbody></table></div></div><div class="NLM_p">Calculated physicochemical properties for selected compounds with varying A-rings are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. These data show that cell shifts for both the benzoisothiazole and indazole analogues are much reduced compared with azabenzofuran analogue <b>3</b>. Azabenzofuran analogue <b>4</b>, which has a less polar hydroxamate substituent and an A-ring substituted with fluorine, has more similar cell shifts to both benzoisothiazoles and indazole <b>13</b>. High donor and acceptor count (>11) is the strongest correlate with increased cell shift; compare <b>1</b> and <b>13</b> and <b>3</b> and <b>4</b>, presumably due to reduced membrane permeability. This difference is more marked in A375 cells. From these data, it is apparent that the indazole and benzoisothiazole scaffolds achieve increased cell potency by more optimal positioning of polar functionality.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Physicochemical Properties for Selected Azabenzofuran, Indazole, And Bezoisothiazole Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">scaffold</th><th class="colsep0 rowsep0" align="center" char=".">NAcc<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">NDon<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">TPSA<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">ClogP<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">HCT116 cell shift<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">A375 cell shift<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">azabenzofuran</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">2.11</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">3.42</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">indazole</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">3.32</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">3.06</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">benzoisothiazole</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">3.67</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">104</td><td class="colsep0 rowsep0" align="char" char=".">2.84</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Number of hydrogen bond acceptors.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Number of hydrogen bond donors.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Topological polar surface area.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Calculated using Daylight v4.94.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">(HCT cell proliferation EC<sub>50</sub>)/(MEK HTRF IC<sub>50</sub>).</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">(A375 cell proliferation EC<sub>50</sub>)/(MEK HTRF IC<sub>50</sub>).</p></div></div></div><div class="NLM_p">When dosed in rats, compound <b>19</b> showed much reduced clearance and â¼5-fold higher oral exposure compared with <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). However, as <b>19</b> is highly plasma protein bound, the unbound clearance is no better than for <b>1</b> (1875 cf. 923 mL/min/kg) and unbound oral AUC is very similar (0.046 cf. 0.040 Î¼MÂ·h). As in the absence of active transport or restricted permeability the unbound fraction of drugs drives efficacy, it was concluded that compound <b>19</b> does not improve on <b>1</b> and it was not tested further. Compound <b>18</b> was not progressed further, as it is a potent CYP2C9 and CYP2C19 inhibitor.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Rat PK Data for <b>19</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">PPB<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)/route</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>(mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a>(h)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a>(L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a>(Î¼MÂ·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a>(%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">99.2</td><td class="colsep0 rowsep0" align="left">1/IV</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">5/PO<sub>(solution)</sub></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Clearance.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Half-life.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Area under the curve.</p></div><div class="footnote" id="t6fn6"><sup>f</sup><p class="last">Bioavailability. Vehicle for oral dosing: 60% PEG 400.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, using structure-based design leveraging key information from a previously disclosed azabenzofuran series, we have discovered novel allosteric MEK inhibitors which, partly through strengthened interaction with Ser212, display improved potency in cellular assays. The most potent compound discovered, indazole <b>1</b>, is efficacious at low doses in a human tumor xenograft model.</div><div class="NLM_p last">The relative contributions to potency of the CâH and NâH H-bond donors in the benzoisothiazole and indazole scaffolds cannot be determined from comparison of the biochemical and cellular data presented here. However, it is clear that the H-bond acceptor of both these scaffolds is ideally positioned and facilitates excellent potency in either case. This result is at odds with previous evidence from the literature which suggests that the H-bond acceptor should be positioned next to the ring junction on 6,5-fused scaffolds, as in <b>2</b>. In this regard, the topology of MEK inhibitors such as <b>1</b> and <b>19</b> is unique. Additionally, taken together, the data on benzofuran, indazole, and benzoisothiazole biaryl amine allosteric MEK inhibitors show that the design of the bicyclic A-ring is critical to achieving a balance of potency and desirable ADME properties. Further details of related compounds which build on these discoveries will be disclosed in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51836" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51836" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> General Experimental Conditions</h4><div class="NLM_p">All solvents and reagents were used as obtained. <sup>1</sup>H NMR spectra were recorded at ambient temperature using a Varian Unity Inova (400 MHz) spectrometer with a triple resonance 5 mm probe. Chemical shifts are expressed in ppm relative to tetramethylsilane.</div><div class="NLM_p last">LC-MS experiments to determine retention times (<i>R</i><sub>T</sub>) and associated mass ions were performed using various methods which are fully described in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. Compounds <b>3</b> and <b>4</b> were prepared according to the patented procedures.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> All final compounds were assessed for purity by LC-MS and found to be â¥95% purity.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 2-Bromo-4-fluoro-benzoic Acid <i>tert</i>-Butyl Ester (<b>5</b>)</h3><div class="NLM_p last">To a suspension of 2-bromo-4-fluoro-benzoic acid (28.5 g, 0.13 mol) in DCM (500 mL) at rt was added oxalyl chloride (11.35 mL, 0.26 mmol) followed by DMF (0.05 mL, catalytic, CARE vigorous gas evolution), and the reaction mixture stirred for 3 h. The reaction mixture was concentrated in vacuo and the residue dissolved in DCM (500 mL) before treatment with a solution of <i>tert</i>-butanol (28.5 g, 0.26 mol) and pyridine (20.5 g, 0.26 mol). The resultant mixture was stirred at rt for 3 days before it was diluted with DCM and washed (1 M aqueous sodium hydroxide, water, 0.1 M aqueous HCl, water), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give a yellow oil. The crude oil was subjected to flash chromatography (Si-PPC, gradient 0â20% ethyl acetate in cylcohexane) to give the title compound as a colorless oil (15.2 g, 42%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ ppm 7.76â7.73 (1H, m), 7.37 (1H, dd, <i>J</i> = 8.4, 2.5 Hz), 7.05 (1H, ddd, <i>J</i> = 8.7, 7.7, 2.5 Hz), 1.60 (9H, s).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 2-Bromo-4-fluoro-3-formyl-benzoic Acid <i>tert</i>-Butyl Ester (<b>6</b>)</h3><div class="NLM_p last">To a cold (â78 Â°C) solution of diisopropylamine (11.3 mL, 80.3 mmol) in THF (200 mL) was added <i>n</i>-butyllithium (30 mL, 2.5 M in hexanes, 75 mmol), and the mixture stirred for 30 min. A solution of 2-bromo-4-fluoro-benzoic acid <i>tert</i>-butyl ester (20.0 g, 73 mmol) in THF (10 mL) was added dropwise, and the pale-orange solution stirred at â75 Â°C for 1.5 h. DMF (10.6 g, 146 mmol) was added, and the mixture stirred for a further 10 min before quenching with water. The products were partitioned between diethyl ether and water, and the organic layer was separated, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give the title compound as a yellow solid (20 g, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) Î´ ppm 10.4 (1H, s), 7.80â7.73 (1H, m), 7.17 (1H, t, <i>J</i> = 9.1 Hz), 1.62 (9H, s).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 4-Bromo-1<i>H</i>-indazole-5-carboxylic Acid <i>tert</i>-Butyl Ester (<b>7</b>)</h3><div class="NLM_p last">A biphasic solution of 2-bromo-4-fluoro-3-formyl-benzoic acid <i>tert</i>-butyl ester (19.5 g, 65 mmol), DME (80 mL), and hydrazine hydrate (30 mL) was heated at 90 Â°C for 1.5 h. After cooling, volatile solvent was removed in vacuo and the products were partitioned between ethyl acetate and saturated aqueous ammonium chloride. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give the title compound as a tan solid (17.2 g, 89%). LC-MS (method B): <i>R</i><sub>T</sub> = 3.63 min, [M + CH<sub>3</sub>CN + H]<sup>+</sup> = 338/340, [M â H]<sup>â</sup> = 295/297. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 8.22 (1 H, d, <i>J</i> = 1.0 Hz), 7.82 (1 H, d, <i>J</i> = 8.7 Hz), 7.44 (1 H, dd, <i>J</i> = 8.7, 1.0 Hz), 1.43 (9 H, s).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4-Bromo-indazole-1,5-dicarboxylic Acid di-<i>tert</i>-Butyl Ester (<b>8</b>)</h3><div class="NLM_p last">To a solution of 4-bromo-1<i>H</i>-indazole-5-carboxylic acid <i>tert</i>-butyl ester (12.0 g, 40 mmol) and triethylamine (6.1 mL, 44 mmol) in DCM (200 mL) was added di-<i>tert</i>-butyl-dicarbonate (9.6 g, 44 mmol), and the reaction mixture stirred at rt for 18 h. The reaction mixture was diluted with DCM, washed (saturated aqueous NaHCO<sub>3</sub>, water), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo in the presence of diatomaceous earth. The crude product was subjected to flash chromatography (Si-PPC, gradient 0â10% ethyl acetate in cyclohexane) to give the title compound as an off-white solid (8.5 g, 50%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 8.29 (1H, s), 8.18â8.10 (1H, m), 7.92 (1H, d, <i>J</i> = 8.7 Hz), 1.70 (9H, s), 1.63 (9H, s).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 4-(2-Fluoro-4-trimethylsilanyl-phenylamino)indazole 1,5-Dicarboxylic Acid di-<i>tert</i>-Butyl Ester (<b>9</b>)</h3><div class="NLM_p last">A solution of 2-fluoro-4-trimethylsilanyl-phenylamine (4.4 g, 24 mmol) in toluene (80 mL) was added to a mixture of 4-bromo-indazole-1,5-dicarboxylic acid di-<i>tert</i>-butyl ester (8.0 g, 20 mmol), Pd<sub>2</sub>dba<sub>3</sub> (456 mg, 2.5 mol %), xantphos (576 mg, 5 mol %), and potassium phosphate tribasic (5.96 g, 28 mmol) under nitrogen. The atmosphere was evacuated and backfilled with nitrogen, and then the reaction mixture heated at 100 Â°C for 4 h. The cooled reaction mixture was diluted with ethyl acetate, filtered through Celite, and the filtrate concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, dry loading on diatomaceous earth, gradient 0â10% ethyl acetate in cyclohexane) to give a solid which was triturated in methanol to give the title compound as a white solid (7.02 g, 70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 10.03 (1H, s), 8.05 (1H, d, <i>J</i> = 9.0 Hz), 7.57 (1H, dd, <i>J</i> = 9.0, 0.8 Hz), 7.28â7.18 (4H, m), 1.68 (9H, s), 1.63 (9H, s), 0.28 (9H, s).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-(2-Fluoro-4-iodophenylamino)-1<i>H</i>-indazole-5-carboxylic Acid (<b>10a</b>)</h3><div class="NLM_p last">To a solution of 4-(2-fluoro-4-trimethylsilanylphenylamino)-indazole-1,5-dicarboxylic acid di-<i>tert</i>-butyl ester (5.0 g, 10 mmol) in DCM (20 mL) at 0 Â°C was added iodine monochloride as a solution in DCM (20 mL, 1N, 20 mmol). The reaction mixture was stirred at 0 Â°C for 15 min and then diluted with saturated aqueous sodium thiosulfate solution (10 mL) and extracted with DCM. The combined organic extracts were washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to yield the title compound as a tan foam. The foam was dissolved in DCM (25 mL) and TFA (15 mL) added. The reaction mixture was stirred at rt for 2 h before being concentrated in vacuo. The resultant residue was triturated in cyclohexane to give the title compound as a grayâpink solid (4.1 g, quantitative). LC-MS (method B): <i>R</i><sub>T</sub> = 3.23 min, [M + H]<sup>+</sup> = 398. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ ppm 10.2 (1 H, s), 7.84 (1 H, d, <i>J</i> = 8.9 Hz), 7.78 (1 H, d, <i>J</i> = 9.9 Hz), 7.58 (1 H, d, <i>J</i> = 8.3 Hz), 7.16 (1 H, t, <i>J</i> = 8.5 Hz), 7.02 (1 H, s), 6.96 (1 H, d, <i>J</i> = 8.9 Hz).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-(2-Fluoro-4-iodophenylamino)-1<i>H</i>-indazole-5-carboxylic Acid (2-vinyloxyethoxy)-amide</h3><div class="NLM_p last">To a solution of 4-(2-fluoro-4-iodophenylamino)-1<i>H</i>-indazole-5-carboxylic acid (2.14 g, 5.39 mmol) and <i>O</i>-(2-vinyloxy-ethyl)-hydroxylamine (668 mg, 6.50 mmol) in DMF (50 mL) was added EDCI hydrochloride (1.14 g, 5.93 mmol), HOBt (0.80 g, 5.93 mmol), and DIPEA (1 mL, 5.93 mmol). The reaction mixture was stirred at rt for 2 h before being concentrated in vacuo. The resultant residue was dissolved in ethyl acetate (30 mL), washed with aqueous saturated sodium bicarbonate solution (300 mL), and the aqueous phase extracted with ethyl acetate (2 Ã 20 mL). The combined organic extracts were washed with brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant residue was subjected to flash chromatography (SiO<sub>2</sub>, gradient 0â100% ethylacetate in cyclohexane) to give the title compound as a pale-yellow solid (1.85 g, 71%). LC-MS (method B): <i>R</i><sub>T</sub> = 3.52 min, [M â H]<sup>+</sup> = 481. <sup>1</sup>H NMR (CD<sub>3</sub>OD) Î´ ppm 7.57 (1 H, dd, <i>J</i> = 10.2, 1.9 Hz), 7.53 (1 H, d, <i>J</i> = 8.7 Hz), 7.45 (1 H, ddd, <i>J</i> = 8.4, 1.9, 1.1 Hz), 7.37 (1 H, s), 7.07 (1 H, d, <i>J</i> = 8.8 Hz), 6.96 (1 H, t, <i>J</i> = 8.6 Hz), 6.50 (1 H, dd, <i>J</i> = 14.3, 6.8 Hz), 4.23 (1 H, dd, <i>J</i> = 14.4, 2.05 Hz), 4.16â4.15 (2 H, m), 3.99â3.99 (3 H, m).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 4-(2-Fluoro-4-iodophenylamino)-1<i>H</i>-indazole-5-carboxylic Acid (2-Hydroxyethoxy)-amide (<b>1</b>)</h3><div class="NLM_p last">To a solution of 4-(2-fluoro-4-iodophenylamino)-1<i>H</i>-indazole-5-carboxylic acid (2-vinyloxyethoxy)-amide (1.85 g, 3.84 mmol) in methanol (40 mL) was added hydrochloric acid (3 mL, 1N, 3 mmol). The reaction mixture was stirred at rt for 1 h, during which an off-white solid precipitated. The reaction mixture was concentrated in vacuo and the residue triturated with hot methanol/water (10 mL, 1:1). The product was collected by filtration and dried in vacuo to yield the title compound as an off white solid (1.26 g, 72%). LC-MS (method A): <i>R</i><sub>T</sub> = 8.28 min, [M + H]<sup>+</sup> = 457. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) Î´ ppm 13.20 (1 H, s), 11.61 (1 H, s), 9.93 (1 H, s), 7.66 (1 H, dd, <i>J</i> = 10.3, 1.9 Hz), 7.46 (1 H, d, <i>J</i> = 8.8 Hz), 7.42 (1 H, dd, <i>J</i> = 8.5, 1.8 Hz), 7.24 (1 H, s), 7.01 (1 H, d, <i>J</i> = 8.8 Hz), 6.91 (1 H, t, <i>J</i> = 8.6 Hz), 4.68 (1 H, s), 3.85 (2 H, dd, <i>J</i> = 5.4, 4.5 Hz), 3.56 (2 H, t, <i>J</i> = 4.8 Hz). HRMS: calculated isotopic <i>M</i><sub>w</sub> (M + Na), 478.9992; observed isotopic <i>M</i><sub>w</sub> (M + Na), 479.0080; confirmed formula, C<sub>16</sub>H<sub>14</sub>FIN<sub>4</sub>O<sub>3</sub>; high resolution error, 18.4 ppm.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2,3-Difluoro-4-methyl-benzoic Acid <i>tert</i>-Butyl Ester (<b>20</b>)</h3><div class="NLM_p last">A mixture of 2,3-difluoro-4-methyl-benzoic acid (20.0 g, 116 mmol), di-<i>tert</i>-butyl dicarbonate (25.0 g, 116 mmol), and DMAP (2.0 g, 16.4 mmol) in <i>tert</i>-butanol (500 mL) was stirred at 45 Â°C for 5 h before being concentrated in vacuo. The resultant residue was triturated in diethyl ether and filtered. The filtrate was concentrated in vacuo to give a residue which was partitioned between ethyl acetate and a 1 M aqueous solution of hydrochloric acid. The organic layer was separated and washed with a saturated aqueous solution of sodium hydrogen carbonate followed by brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give the title compound as a colorless oil (17.3 g, 65%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 7.51 (1 H, ddd, <i>J</i> = 8.3, 6.6, 1.9 Hz), 6.95 (1 H, m), 2.33 (3 H, d, <i>J</i> = 2.3 Hz), 1.59 (9 H, s).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-Bromomethyl-2,3-difluoro-benzoic Acid <i>tert</i>-Butyl Ester (<b>21</b>)</h3><div class="NLM_p last">A solution of 2,3-difluoro-4-methyl-benzoic acid <i>tert</i>-butyl ester (17.3 g, 75.9 mmol) and <i>N</i>-bromosuccinimide (13.5 g, 75.9 mmol) in carbon tetrachloride (250 mL) was degassed for 10 min. AIBN (1.2 g, 7.32 mmol) was added, and the reaction mixture was stirred at reflux for 18 h before being cooled to rt and filtered. The filtrate was concentrated in vacuo to give a residue which was subjected to flash chromatography (Si-PPC, gradient 0â10% TBME in cyclohexane) to afford the title compound as a colorless oil (16.7 g, contaminated by 25% of starting material). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 7.61 (1 H, ddd, <i>J</i> = 8.3, 6.4, 2.1 Hz), 7.18 (1 H, ddd, <i>J</i> = 8.1, 6.4, 1.8 Hz), 4.49 (2 H, d, <i>J</i> = 1.3 Hz), 1.59 (9 H, s).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2,3-Difluoro-4-formyl-benzoic Acid <i>tert</i>-Butyl Ester (<b>22</b>)</h3><div class="NLM_p last">To a solution of 4-bromomethyl-2,3-difluoro-benzoic acid <i>tert</i>-butyl ester (12.9 g, 42.1 mmol) in DMSO (80 mL) and DCM (40 mL) at 0 Â°C was added trimethylamine <i>N</i>-oxide (3.4 g, 45.3 mmol). The reaction mixture was stirred at rt for 18 h before being concentrated in vacuo. The resultant residue was partitioned between iced water and ethyl acetate. The organic layer was separated and washed with brine twice, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0â10% TBME in cyclohexane) to afford the title compound as a white solid (4.34 g, 43%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 10.38 (1 H, d, <i>J</i> = 0.8 Hz), 7.71 (1 H, dddd, <i>J</i> = 7.4, 5.6, 1.7, 0.8 Hz), 7.63 (1 H, ddd, <i>J</i> = 7.4, 5.6, 1.5 Hz), 1.61 (9 H, s).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 3-Benzylsulfanyl-2-fluoro-4-formyl-benzoic Acid <i>tert</i>-Butyl Ester (<b>23</b>)</h3><div class="NLM_p last">To a solution of potassium <i>tert</i>-butoxide (2.0 g, 17.9 mmol) in anhydrous THF (80 mL) was added benzyl mercaptan (2.1 mL, 17.9 mmol). The reaction mixture was stirred at rt for 5 min before being cooled to â30 Â°C. A solution of 2,3-difluoro-4-formyl-benzoic acid <i>tert</i>-butyl ester (4.34 g, 17.9 mmol) in anhydrous THF (20 mL) was added dropwise over 15 min, and the resultant mixture was stirred at â30 Â°C for 30 min before being quenched by addition of water and extracted with ethyl acetate. The organic layer was separated, washed with water followed by brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give the title compound as a yellow oil (6.2 g, 100%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 10.20 (1 H, d, <i>J</i> = 0.6 Hz), 7.84 (1 H, ddd, <i>J</i> = 8.0, 6.8, 0.7 Hz), 7.59 (1 H, dd, <i>J</i> = 8.0, 0.9 Hz), 7.19 (3 H, m), 7.05 (2 H, m), 4.07 (2 H, s), 1.63 (9 H, s).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 7-Fluoro-benzo[<i>d</i>]isothiazole-6-carboxylic Acid <i>tert</i>-Butyl Ester (<b>24</b>)</h3><div class="NLM_p last">To a solution of 3-benzylsulfanyl-2-fluoro-4-formyl-benzoic acid <i>tert</i>-butyl ester (6.20 g, 17.9 mmol) in DCM (100 mL) was added sulfuryl chloride (2.9 mL, 35.8 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated in vacuo. The resultant residue was azeotroped with toluene twice and then taken up in THF (50 mL). The resultant solution was cooled to 0 Â°C, and a 2 M solution of ammonia in methanol (100 mL) was added. The reaction mixture was stirred at rt for 1 h and then concentrated in vacuo. The resultant residue was partitioned between ethyl acetate and a saturated aqueous solution of sodium hydrogen carbonate. The organic layer was separated and washed with water followed by brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated in vacuo. The residue was subjected to flash chromatography (Si-PPC, gradient 0â10% diethyl ether in pentane) to give the title compound as a yellow solid (2.96 g, 65%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 8.93 (1 H, dd, <i>J</i> = 4.1, 0.5 Hz), 7.91 (1 H, ddd, <i>J</i> = 8.3, 5.8, 0.5 Hz), 7.84 (1 H, d, <i>J</i> = 8.3 Hz), 1.64 (9 H, s).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid <i>tert</i>-Butyl Ester (<b>25</b>)</h3><div class="NLM_p last">To a solution of 7-fluoro-benzo[<i>d</i>]isothiazole-6-carboxylic acid <i>tert</i>-butyl ester (1.26 g, 5.0 mmol) and 2-fluoro-4-iodo-phenylamine (1.18 g, 5.0 mmol) in anhydrous THF (25 mL) at â78 Â°C was added a 1.0 M solution of LHMDS in hexanes (10.0 mL, 10.0 mmol) under a nitrogen atmosphere. The reaction mixture was allowed to warm to rt and then stirred for 30 min before being quenched by the addition of a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate. The organic layer was separated and washed with water followed by brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated in vacuo. The residue was subjected to flash chromatography (Si-PPC, gradient 0â10% TBME in cyclohexane) to give the title compound as a yellow solid (717 mg, 30%). LC-MS (method B): <i>R</i><sub>T</sub> = 5.14 min, [M + H]<sup>+</sup> = 471. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 9.85 (1 H, s), 8.77 (1 H, s), 7.99 (1 H, dd, <i>J</i> = 8.6, 0.5 Hz), 7.49â7.48 (3 H, m), 6.90 (1 H, t, <i>J</i> = 8.3 Hz), 1.65 (9 H, s).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid (<b>26</b>)</h3><div class="NLM_p last">To a solution of 7-(2-fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic acid <i>tert</i>-butyl ester (710 mg, 1.51 mmol) in DCM (5 mL) were added water (0.15 mL) and TFA (5 mL). The reaction mixture was stirred at rt for 1 h before being concentrated in vacuo. The resultant residue was azeotroped with toluene to give the title compound as a yellow solid (571 mg, 91%). LC-MS (method B): <i>R</i><sub>T</sub> = 3.95 min, [M + H]<sup>+</sup> = 415. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 9.69 (1 H, s), 8.79 (1 H, s), 8.08 (1 H, d, <i>J</i> = 8.6 Hz), 7.55â7.54 (2 H, m), 7.49 (1 H, d, <i>J</i> = 8.6 Hz), 7.01 (1 H, t, <i>J</i> = 8.3 Hz).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid (2-Vinyloxy-ethoxy)-amide</h3><div class="NLM_p last">To a solution of 7-(2-fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic acid (328 mg, 0.79 mmol) and DIPEA (0.41 mL, 2.37 mmol) in DMF (2 mL) were added <i>O</i>-(2-vinyloxy-ethyl)-hydroxylamine (163 mg, 1.58 mmol), EDCI (303 mg, 1.58 mmol), and HOBt (213 mg, 1.58 mmol). The reaction mixture was stirred for 18 h at rt and then diluted with ethyl acetate and washed with water, then a saturated aqueous solution of sodium bicarbonate, and then brine before being dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0â100% TBME in cyclohexane) to afford the title compound as a yellow foam (194 mg, 49%). LC-MS (method B): <i>R</i><sub>T</sub> = 3.99 min, [M + H]<sup>+</sup> = 500. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 9.38 (1 H, s), 8.99 (1 H, s), 8.81 (1 H, s), 8.29â6.73 (2 H, m), 6.82 (1 H, t, <i>J</i> = 8.8 Hz), 6.53 (1 H, dd, <i>J</i> = 14.4, 6.8 Hz), 4.33 (2 H, m), 4.24 (1 H, m), 4.11 (1 H, m), 4.03 (2 H, m).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid (2-Hydroxy-ethoxy)-amide (<b>18</b>)</h3><div class="NLM_p last">To a solution of 7-(2-fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic acid (2-vinyloxy-ethoxy)-amide (187 mg, 0.37 mmol) in methanol (4 mL) was added a 1.0 M aqueous solution of hydrochloric acid (0.75 mL, 0.75 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated under reduced pressure. The residue was taken up in ethyl acetate and washed with a saturated aqueous solution of sodium bicarbonate and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The residue was subjected to flash chromatography (Si-PPC, gradient 0â100%, ethyl acetate in DCM) to give the title compound as a yellow solid (128 mg, 72%). LC-MS (method A): <i>R</i><sub>T</sub> = 9.81 min, [M + H]<sup>+</sup> = 474. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 9.33 (1 H, s), 8.86 (1 H, s), 8.77 (1 H, s), 7.55â7.40 (4 H, m), 6.84 (1 H, t, <i>J</i> = 8.3 Hz), 4.10 (2 H, t, <i>J</i> = 4.2 Hz), 3.91 (1 H, t, <i>J</i> = 6.4 Hz), 3.80 (2 H, t, <i>J</i> = 4.5 Hz).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid ((<i>R</i>)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide</h3><div class="NLM_p last">To a solution of 7-(2-fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic acid (377 mg, 0.91 mmol) and DIPEA (0.47 mL, 2.73 mmol) in DMF (4 mL) were added <i>O</i>-((<i>R</i>)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-hydroxylamine (268 mg, 1.82 mmol), EDCI (349 mg, 1.82 mmol), and HOBt (246 mg, 1.82 mmol). The reaction mixture was stirred for 18 h at rt before being diluted with ethyl acetate. The resultant solution was washed with water followed by a saturated aqueous solution of sodium hydrogen carbonate and then brine before being dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0â100% TBME in cyclohexane) to give the title compound as a yellow solid (266 mg, 54%). LC-MS (method B): <i>R</i><sub>T</sub> = 4.04 min, [M + H]<sup>+</sup> = 544. <sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ ppm 8.88 (1 H, s), 8.63 (1 H, s), 8.28 (1 H, s), 7.04 (1 H, d, <i>J</i> = 8.3 Hz), 6.98 (1 H, dd, <i>J</i> = 9.5, 1.9 Hz), 6.94 (2 H, m), 6.30 (1 H, t, <i>J</i> = 8.3 Hz), 3.96 (1 H, m), 3.62â3.60 (3 H, m), 3.35 (1 H, m), 0.95 (3 H, s), 0.88 (3 H, s).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 7-(2-Fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic Acid ((<i>R</i>)-2,3-Dihydroxy-propoxy)amide (<b>19</b>)</h3><div class="NLM_p last">To a solution of 7-(2-fluoro-4-iodo-phenylamino)-benzo[<i>d</i>]isothiazole-6-carboxylic acid ((<i>R</i>)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide (263 mg, 0.48 mmol) in methanol (10 mL) was added a 1.0 M aqueous solution of hydrochloric acid (0.97 mL). The reaction mixture was stirred at rt for 18 h before being concentrated in vacuo. The resultant residue was taken up in ethyl acetate, washed with a saturated aqueous solution of sodium hydrogen carbonate and then brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resultant residue was subjected to flash chromatography (Si-PPC, gradient 0â100% ethyl acetate in DCM) to give the title compound as a yellow solid (127 mg, 53%). LC-MS (method A): <i>R</i><sub>T</sub> = 9.05 min, [M + H]<sup>+</sup> = 504. <sup>1</sup>H NMR (CD<sub>3</sub>OD) Î´ ppm 8.88 (1 H, s), 7.74 (1 H, d, <i>J</i> = 8.4 Hz), 7.61 (1 H, d, <i>J</i> = 8.3 Hz), 7.53 (1 H, dd, <i>J</i> = 10.0, 1.9 Hz), 7.44 (1 H, ddd, <i>J</i> = 8.4, 1.9, 1.1 Hz), 6.76 (1 H, t, <i>J</i> = 8.5 Hz), 4.05 (1 H, dd, <i>J</i> = 10.0, 3.5 Hz), 3.96â3.83 (2 H, m), 3.63â3.52 (2 H, m). HRMS: calculated isotopic <i>M</i><sub>w</sub> (M + Na), 525.9710; observed isotopic <i>M</i><sub>w</sub> (M + Na), 525.9601; confirmed formula, C<sub>17</sub>H<sub>15</sub>FIN<sub>3</sub>O<sub>4</sub>S; high resolution error, â20.07 ppm.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> In Vitro Methods for the Determination of MEK Inhibition, Cellular Levels of Phospho-ERK, and Cell Proliferation</h3><div id="sec4_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> MEK1 Inhibition Assay</h4><div class="NLM_p last">A homogeneous time-resolved fluorescence assay (HTRF) was used to test for inhibition of kinase activity. A constitutively active MEK1 was obtained from Invitrogen and was tested at a concentration of 15 nM with 50 Î¼M ATP, 50 nM unactive ERK1, and the test compound in a 25 mM HEPES buffer, pH 7.5, containing 10 mM MgCl<sub>2</sub>, 5 mM Î²-glycerophosphate, 0.1 mM sodium orthovanadate, and 0.1 mg/mL Triton X 100. The kinase assay was carried out for 30 min at 25 Â°C and was terminated by the addition of EDTA. HTRF reagents (CisBiol) were added and time-resolved fluorescence was read using a Wallac Victor V (Perkin-Elmer). IC<sub>50</sub> values quoted are the result of at least two separate determinations where the results were within 2-fold of eachother and were calculated using the KLfit software package (version 2.0.5).</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Assay for Cellular Levels of Phospho-ERK</h4><div class="NLM_p last">Cells (HCT116 or A375) were seeded at 26700/well into collagen-coated 96-well plates and were incubated overnight under normal tissue culture conditions. The following day, the cells were exposed to MEK inhibitors for 2 h. At the end of this time, the cells were fixed and permeabilized by incubation in 2% formaldehyde for 45 min followed by 100% ice-cold methanol for 10 min. The fixed and permeabilized cells were washed with PBS and blocked with 3% BSA in Tris buffered saline plus Tween 20 (TBST) for 1 h at 37 Â°C. At the end of this time, the blocking solution was replaced with an antiphospho-ERK antibody raised in rabbit (New England Biolabs) at a dilution of 1:1000 made in blocking solution and the cells were incubated overnight at 4 Â°C, followed by washing and incubation with antirabbit-Igâ Alexa Flour 488 (Invitrogen) at a dilution of 1:1000 in blocking solution for 2 h at rt. Following washing, the cells were incubated with 1.5 Î¼M propridium iodide for 2 h in the dark and read on a high content imager (Acumen, TTP LabTech) in the red and green channels to measure P-ERK content and cell number. EC<sub>50</sub> values quoted are the result of at least two separate determinations, where the results were within 2-fold of eachother and were calculated using the KLfit software package (version 2.0.5).</div></div><div id="sec4_21_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Cell Proliferation Assay</h4><div class="NLM_p last">Cells (HCT116 or A375) were seeded at 26700/well into collagen-coated 96-well plates and were incubated overnight under normal tissue culture conditions. The following day, the cells were exposed to MEK inhibitors for 72 h under normal tissue culture conditions. At the end of this time, the cells were equilibrated to rt and mixed 1:1 with Cell Titer Glo reagent prepared as indicated by the supplier (Promega), followed by a 10 min incubation. Luminescence was read using a TopCount (Perkin-Elmer). EC<sub>50</sub> values quoted are the result of at least two separate determinations, where the results were within 2-fold of eachother and were calculated using the KLfit software package (version 2.0.5).</div></div><div id="sec4_21_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Molecular Modeling Methods</h4><div class="NLM_p last">All molecular modeling experiments were carried out using software from SchrÃ¶dinger Inc. The crystal structure of MEK1 (extracted from the cocrystal with <b>3</b>, PDB reference <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V01">3V01</a>) was prepared using the Protein Preparation Wizard in Maestro (Protein Preparation Wizard, SchrÃ¶dinger, LLC, New York, NY), which assigns bond orders, adds hydrogen atoms, deletes water molecules, and generates appropriate protonation states. The prepared protein structure was then minimized using OPLS2001 (until the rmsd reached 0.3 Ã) and used to generate the receptor grids for docking. The binding site was defined using the native ligand and selecting the option âdocking ligands similar in sizeâ. The ligand structures were built in Maestro and prepared for docking using LigPrep 2.0 (LigPrep, SchrÃ¶dinger, LLC, New York, NY). The docking experiments were carried out with Glide 4.0<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> in Extra Precision mode, using the default parameters setting. The top five docking poses for each ligand were selected and visually inspected.</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> X-Ray Crystal Structure Determination Method</h3><div id="sec4_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Cloning and Expression</h4><div class="NLM_p last">The truncated (residues 63â393)MEK1 was cloned from a wt MEK1 full length construct via PCR and subcloned into pET24b (Novagen) as previously described.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The recombinant MEK1 was expressed in <i>Escherichia coli</i> (Rosetta 2 pLys S) and grown in Ultra Yield Flasks (Thomson Instrument Company) TB media/MOPS/glycerol at 37 Â°C to an O.D. of 1 (600 nm). The cells were then placed at 16 Â°C and induced after 30 min with 0.5 mM IPTG and allowed to grow an additional 18 h.</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Protein Purification and Crystallization</h4><div class="NLM_p last">MEK1 was purified using Cobalt immobilized metal affinity resin (TALON), ion exchange, and size exclusion chromatography. The protein was concentrated to 15 mg/mL and incubated with 10-fold molar excess inhibitor plus 1 mM MgAMP-PNP before crystallization. MEK1 crystals grew from hanging drop vapor diffusion using 12% w/v PEG 8000, 0.4 M NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>, and 0.1 M HEPES pH 6.9 at 18 Â°C. MEK1 crystals belonging to the space group <i>P</i>62 and unit cell <i>a</i> = 81 Ã and <i>c</i> = 129 Ã were previously described.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec4_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Structure Determination and Refinement</h4><div class="NLM_p last">Synchrotron data was collected at the Advanced Light Source (ALS) beamline 5.0.2. Diffraction data to 2.7 Ã at 100 K was processed using HKL2000<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> suite of programs. Molecular replacement was performed using MOLREP in CCP4<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> suite with PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1S9J">1S9J</a> as the starting model. Refinement was conducted using REFMAC5.2. The refinement statistics are summarized in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/jm2017094">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Methods and further results for the in vivo pharmacodynamic and efficacy studies involving <b>1</b>; experimental procedures for the preparation of compounds <b>12</b>â<b>17</b>; NMR spectra for <b>1</b> and <b>19</b>; data collection and refinement statistics for complexes of <b>3</b> and <b>1</b> with MEK1; kinase panel data for <b>1</b>; rat in vivo metabolite identification for <b>1</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2017094/suppl_file/jm2017094_si_001.pdf">jm2017094_si_001.pdf (188.97 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm2017094" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Heald</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bfcdd0dddacdcb91d7daded3dbffd8d3cfd891dcd0d2"><span class="__cf_email__" data-cfemail="42302d202730366c2a27232e2602252e32256c212d2f">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Jackson</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal Savy</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Jones</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emanuela Gancia</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brenda Burton</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Newman</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Boggs</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Chan</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jocelyn Chan</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edna Choo</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Merchant</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Rudewicz</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Ultsch</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Wiesmann</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Yue</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcia Belvin</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Price</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green Centre,
Flex Meadow, Harlow, Essex CM19 5TR, U.K.</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d471e2798-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Kirk Robarge, Mark Zak, and Paul Gibbons for helpful discussions and collection of experimental data.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations Used</h2><tr><td class="NLM_term">AMP-PNP</td><td class="NLM_def"><p class="first last">adenylyl-imidodiphosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3â²-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IPTG</td><td class="NLM_def"><p class="first last">isopropyl-Î²-<span class="smallcaps smallerCapital">d</span>-thiogalactopyranoside</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">MadinâDarby canine kidney cells</p></td></tr><tr><td class="NLM_term">MOPS</td><td class="NLM_def"><p class="first last">3-(<i>N</i>-morpholino)propanesulfonic acid</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>dba<sub>3</sub></td><td class="NLM_def"><p class="first last">tris-(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">Si-PPC</td><td class="NLM_def"><p class="first last">prepacked silica flash chromatography cartridge (Isolute SPE, Biotage SNAP or ISCO Redisep)</p></td></tr><tr><td class="NLM_term">TBME</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl methyl ether</p></td></tr><tr><td class="NLM_term">xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">â</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0litRABlY7MEYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hoshino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari-I, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, M.</span><span> </span><span class="NLM_article-title">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">â</span> <span class="NLM_lpage">822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fsj.onc.1202367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=9989833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=813-822&author=R.+Hoshinoauthor=Y.+Chantaniauthor=T.+Yamoriauthor=T.+Tsuruoauthor=H.+Okaauthor=O.+Yoshidaauthor=Y.+Shimadaauthor=S.+Ari-Iauthor=H.+Wadaauthor=J.+Fujimotoauthor=M.+Kohno&title=Constitutive+activation+of+the+41-%2F43-kDa+mitogen-activated+protein+kinase+signaling+pathway+in+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span></div><div class="casAuthors">Hoshino, Rika; Chatani, Yuji; Yamori, Takao; Tsuruo, Takashi; Oka, Hiroya; Yoshida, Osamu; Shimada, Yutaka; Ari-i, Shigeki; Wada, Hiromi; Fujimoto, Jiro; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1.  As aberrant activation of signal transducing mols. such as Ras and Raf-1 has been linked with cancer, the authors examd. whether constitutive activation of the 41-/43-kDa MAP kinases is assocd. with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs.  Constitutive activation of the MAP kinases was obsd. in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed esp. high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation.  The authors also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large no. of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue.  Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation.  In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely assocd. with the activation of MEK and p90rsk in all the tumor cells examd.  These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling mols. upstream of Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRICRJXnIoerVg90H21EOLACvtfcHk0ljRXwdeXXXO_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D&md5=719a702e589f259a22f53f7a2be0e94a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202367%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DR.%26aulast%3DChantani%26aufirst%3DY.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DO.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAri-I%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DConstitutive%2520activation%2520of%2520the%252041-%252F43-kDa%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520in%2520human%2520tumors%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D813%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">â</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with â¼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0ljRXwdeXXXO_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3651</span><span class="NLM_x">â</span> <span class="NLM_lpage">3656</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-08-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18559577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlWkurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3651-3656&author=J.+S.+Sebolt-Leopold&title=Advances+in+the+development+of+cancer+therapeutics+directed+against+the+RAS-mitogen-activated+protein+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway</span></div><div class="casAuthors">Sebolt-Leopold, Judith S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3651-3656</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Among mammalian mitogen-activated protein kinase (MAPK) signaling cascades, the extracellular signal-related kinase (ERK) pathway has received the most attention in the oncol. drug discovery arena.  By virtue of its central role in promoting proliferation, survival, and metastasis, this pathway directly affects both the formation and progression of human tumors.  The identification of non-ATP-competitive inhibitors of the MAPK kinase MAPK/ERK kinase (MEK) resulted in the first demonstration that the ERK pathway could be effectively shut down in a highly selective fashion.  Subsequent discovery of the oncogenic nature of B-raf kinase led to the escalation of drug discovery efforts revolving around MEK and RAF.  The emergence of multiple drug candidates targeting these downstream kinases provides us with the means for validating the importance of the RAS-RAF-MEK-ERK signaling cascade in human tumors.  This article highlights the lessons learned in the clin. evaluation of MAPK pathway inhibitors as anticancer agents and the complexities surrounding optimization of their therapeutic potential in light of the challenges posed by genetic heterogeneity within patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGj-KF9xysMLVg90H21EOLACvtfcHk0ljRXwdeXXXO_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlWkurc%253D&md5=872292fa6eba2bc8f97fd454b947c53a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0333%26sid%3Dliteratum%253Aachs%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520cancer%2520therapeutics%2520directed%2520against%2520the%2520RAS-mitogen-activated%2520protein%2520kinase%2520pathway%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3651%26epage%3D3656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span>Thomson Reuters Integrity; <span class="NLM_publisher-name">Thomson Reuters</span>: <span class="NLM_publisher-loc">East Haven, CT</span>; <a href="http://integrity.prous.com/" class="extLink">http://integrity.prous.com/</a> (Accessed <span class="NLM_access-date">December 10, 2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thomson+Reuters+Integrity%3B+Thomson+Reuters%3A+East+Haven%2C+CT%3B+http%3A%2F%2Fintegrity.prous.com%2F+%28Accessed+December+10%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThomson%2520Reuters%2520Integrity%26pub%3DThomson%2520Reuters" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">FrÃ©min, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloche, S.</span><span> </span><span class="NLM_article-title">From basic research to clinical development of MEK1/2 inhibitors for cancer therapy</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1186%2F1756-8722-3-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=20149254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ltFGnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=8&author=C.+Fr%C3%A9minauthor=S.+Meloche&title=From+basic+research+to+clinical+development+of+MEK1%2F2+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From basic research to clinical development of MEK1/2 inhibitors for cancer therapy</span></div><div class="casAuthors">Fremin Christophe; Meloche Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival.  Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes.  Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer.  In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway.  We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXiqh48Jb4JresJRIHUP1ofW6udTcc2ebgdxwmrvrMJbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ltFGnsg%253D%253D&md5=b6b8c91b259b37885fd951001b4bd817</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-8%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9min%26aufirst%3DC.%26aulast%3DMeloche%26aufirst%3DS.%26atitle%3DFrom%2520basic%2520research%2520to%2520clinical%2520development%2520of%2520MEK1%252F2%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yeh, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernat, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, E.</span><span> </span><span class="NLM_article-title">Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1576</span><span class="NLM_x">â</span> <span class="NLM_lpage">1583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-06-1150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17332304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1576-1583&author=T.+C.+Yehauthor=V.+Marshauthor=B.+A.+Bernatauthor=J.+Ballardauthor=H.+Colwellauthor=R.+J.+Evansauthor=J.+Parryauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+Grossauthor=A.+Marlowauthor=B.+Hurleyauthor=J.+Lyssikatosauthor=P.+A.+Leeauthor=J.+D.+Winklerauthor=K.+Kochauthor=E.+Wallace&title=Biological+characterization+of+ARRY-142886+%28AZD6244%29%2C+a+potent%2C+highly+selective+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of ARRY-142886 (AZD6244), a ptent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor</span></div><div class="casAuthors">Yeh, Tammie C.; Marsh, Vivienne; Bernat, Bryan A.; Ballard, Josh; Colwell, Heidi; Evans, Ron J.; Parry, Janet; Smith, Darin; Brandhuber, Barbara J.; Gross, Stefan; Marlow, Allison; Hurley, Brian; Lyssikatos, Joe; Lee, Patrice A.; Winkler, James D.; Koch, Kevin; Wallace, Eli</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1576-1583</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics.  We have developed a highly potent and selective inhibitor of MEK1/2.  The purpose of these studies has been to show the biol. efficacy of ARRY-142886 (AZD6244) in enzymic, cellular, and animal models.  The ability of ARRY-142886 to inhibit purified MEK1 as well as other kinases was evaluated.  Its effects on extracellular signal-regulated kinase (ERK) phosphorylation and proliferation in several cell lines were also detd.  Finally, the inhibitor was tested in HT-29 (colorectal) and BxPC3 (pancreatic) xenograft tumor models.  The IC50 of ARRY-142886 was detd. to be 14 nmol/L against purified MEK1.  This activity is not competitive with ATP, which is consistent with the high specificity of compd. for MEK1/2.  Basal and epidermal growth factor-induced ERK1/2 phosphorylation was inhibited in several cell lines as well as 12-O-tetradecanoylphorbol-13-acetate-induced ERK1/2 phosphorylation in isolated peripheral blood mononuclear cells.  Treatment with ARRY-142886 resulted in the growth inhibition of several cell lines contg. B-Raf and Ras mutations but had no effect on a normal fibroblast cell line.  When dosed orally, ARRY-142886 was capable of inhibiting both ERK1/2 phosphorylation and growth of HT-29 xenograft tumors in nude mice.  Tumor regressions were also seen in a BxPC3 xenograft model.  In addn., tumors remained responsive to growth inhibition after a 7-day dosing holiday.  ARRY-142886 is a potent and selective MEK1/2 inhibitor that is highly active in both in vitro and in vivo tumor models.  This compd. is currently being investigated in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7qJbWopjHu7Vg90H21EOLACvtfcHk0ljId-BMK4vdVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLg%253D&md5=677df690d8016a8b5ad44f46ad1ec027</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1150%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DMarsh%26aufirst%3DV.%26aulast%3DBernat%26aufirst%3DB.%2BA.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DColwell%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DParry%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DMarlow%26aufirst%3DA.%26aulast%3DHurley%26aufirst%3DB.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BA.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DKoch%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DE.%26atitle%3DBiological%2520characterization%2520of%2520ARRY-142886%2520%2528AZD6244%2529%252C%2520a%2520potent%252C%2520highly%2520selective%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1576%26epage%3D1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+McKayauthor=P.+Martinauthor=S.+Steeleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+1%2F2+kinases%3A+mechanism+of+action+in+vivo%2C+pharmacokinetic%2Fpharmacodynamic+relationship%2C+and+potential+for+combination+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0ljId-BMK4vdVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMcKay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DSteele%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%25201%252F2%2520kinases%253A%2520mechanism%2520of%2520action%2520in%2520vivo%252C%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%252C%2520and%2520potential%2520for%2520combination%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2209%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litwiler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span> </span><span class="NLM_article-title">Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1200%2FJCO.2007.14.4956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18390968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1OrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2139-2146&author=A.+A.+Adjeiauthor=R.+B.+Cohenauthor=W.+Franklinauthor=C.+Morrisauthor=D.+Wilsonauthor=J.+R.+Molinaauthor=L.+J.+Hansonauthor=L.+Goreauthor=L.+Chowauthor=S.+Leongauthor=L.+Maloneyauthor=G.+Gordonauthor=H.+Simmonsauthor=A.+Marlowauthor=K.+Litwilerauthor=S.+Brownauthor=G.+Pochauthor=K.+Kaneauthor=J.+Haneyauthor=S.+G.+Eckhardt&title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+the+oral%2C+small-molecule+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor+AZD6244+%28ARRY-142886%29+in+patients+with+advanced+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers</span></div><div class="casAuthors">Adjei, Alex A.; Cohen, Roger B.; Franklin, Wilbur; Morris, Clive; Wilson, David; Molina, Julian R.; Hanson, Lorelei J.; Gore, Lia; Chow, Laura; Leong, Stephen; Maloney, Lara; Gordon, Gilad; Simmons, Heidi; Marlow, Allison; Litwiler, Kevin; Brown, Suzy; Poch, Gregory; Kane, Katie; Haney, Jerry; Eckhardt, S. Gail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2139-2146</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer.  In part A, patients received escalating doses to det. the max.-tolerated dose (MTD).  In both parts, blood samples were collected to assess PK and PD parameters.  In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to receive the MTD or 50% MTD.  Biopsies were collected to det. inhibition of ERK phosphorylation, Ki-67 expression, and BRAF, KRAS, and NRAS mutations.  Fifty-seven patients were enrolled.  MTD in part A was 200 mg bid, but this dose was discontinued in part B because of toxicity.  The 50% MTD (100 mg bid) was well tolerated.  Rash was the most frequent and dose-limiting toxicity.  Most other adverse events were grade 1 or 2.  The PKs were less than dose proportional, with a median half-life of approx. 8 h and inhibition of ERK phosphorylation in peripheral-blood mononuclear cells at all dose levels.  Paired tumor biopsies demonstrated, reduced ERK phosphorylation (geometric mean, 79%).  Five of 20 patients demonstrated â¥ 50% inhibition of Ki-67 expression, and RAF or RAS mutations were detected in 10 of 26 assessable tumor samples.  Nine patients had stable disease (SD) for â¥ 5 mo, including two patients with SD for 19 (thyroid cancer) and 22 (uveal melanoma plus renal cancer) 28-day cycles.  AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose.  PK analyses supported twice-daily dosing.  Prolonged SD was seen in a variety of advanced cancers.  Phase II studies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI2Uc-97FbNbVg90H21EOLACvtfcHk0lgp6HEzdzcEpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1OrtL8%253D&md5=c6f68db45ff4788414ad556f3eaf2acc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.4956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.4956%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DFranklin%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DHanson%26aufirst%3DL.%2BJ.%26aulast%3DGore%26aufirst%3DL.%26aulast%3DChow%26aufirst%3DL.%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DGordon%26aufirst%3DG.%26aulast%3DSimmons%26aufirst%3DH.%26aulast%3DMarlow%26aufirst%3DA.%26aulast%3DLitwiler%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DPoch%26aufirst%3DG.%26aulast%3DKane%26aufirst%3DK.%26aulast%3DHaney%26aufirst%3DJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DPhase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%252C%2520small-molecule%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%2520AZD6244%2520%2528ARRY-142886%2529%2520in%2520patients%2520with%2520advanced%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2139%26epage%3D2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Barrett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltiel, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fergus, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamme, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LePage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przybranowski, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Becelaere, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, W. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span> </span><span class="NLM_article-title">The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD0325901</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6501</span><span class="NLM_x">â</span> <span class="NLM_lpage">6504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6501-6504&author=S.+D.+Barrettauthor=A.+J.+Bridgesauthor=D.+T.+Dudleyauthor=A.+R.+Saltielauthor=J.+H.+Fergusauthor=C.+M.+Flammeauthor=A.+M.+Delaneyauthor=M.+Kaufmanauthor=S.+LePageauthor=W.+R.+Leopoldauthor=S.+A.+Przybranowskiauthor=J.+Sebolt-Leopoldauthor=K.+Van+Becelaereauthor=A.+M.+Dohertyauthor=R.+M.+Kennedyauthor=D.+Marstonauthor=W.+A.+Howardauthor=Y.+Smithauthor=J.+S.+Warmusauthor=H.+Tecle&title=The+discovery+of+the+benzhydroxamate+MEK+inhibitors+CI-1040+and+PD0325901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DS.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DSaltiel%26aufirst%3DA.%2BR.%26aulast%3DFergus%26aufirst%3DJ.%2BH.%26aulast%3DFlamme%26aufirst%3DC.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DLePage%26aufirst%3DS.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DPrzybranowski%26aufirst%3DS.%2BA.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DKennedy%26aufirst%3DR.%2BM.%26aulast%3DMarston%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DY.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DTecle%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520the%2520benzhydroxamate%2520MEK%2520inhibitors%2520CI-1040%2520and%2520PD0325901%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6501%26epage%3D6504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span>ClinicalTrials.gov; <span class="NLM_publisher-name">National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>; <a href="http://www.clinicaltrials.gov/ct2/results?term=AZD6244" class="extLink">http://www.clinicaltrials.gov/ct2/results?term=AZD6244</a> (Accessed <span class="NLM_access-date">December 10, 2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%3B+National+Institutes+of+Health%3A+Bethesda%2C+MD%3B+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DAZD6244+%28Accessed+December+10%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DClinicalTrials.gov%26pub%3DNational%2520Institutes%2520of%2520Health" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakefuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakegawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmartin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">320</span><span class="NLM_x">â</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&issue=4&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+Highly+Potent+and+Selective+MEK+Inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+Solvate%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520MEK%2520Inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520Solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D4%26spage%3D320%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punnoose, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span> </span><span class="NLM_article-title">In Vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4649</span><span class="NLM_x">â</span> <span class="NLM_lpage">4664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-09-0317" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=4649-4664&author=K.+P.+Hoeflichauthor=C.+O%E2%80%99Brienauthor=Z.+Boydauthor=G.+Cavetauthor=S.+Guerreroauthor=K.+Jungauthor=T.+Januarioauthor=H.+Savageauthor=E.+Punnooseauthor=T.+Truongauthor=W.+Zhouauthor=L.+Berryauthor=L.+Murrayauthor=L.+Amlerauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=M.+R.+Lackner&title=In+Vivo+Antitumor+Activity+of+MEK+and+Phosphatidylinositol+3-Kinase+Inhibitors+in+Basal-Like+Breast+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0317%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DBoyd%26aufirst%3DZ.%26aulast%3DCavet%26aufirst%3DG.%26aulast%3DGuerrero%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DK.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DSavage%26aufirst%3DH.%26aulast%3DPunnoose%26aufirst%3DE.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26atitle%3DIn%2520Vivo%2520Antitumor%2520Activity%2520of%2520MEK%2520and%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520in%2520Basal-Like%2520Breast%2520Cancer%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D14%26spage%3D4649%26epage%3D4664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hatzivassiliou1, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliou1author=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+J.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou1%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Price, S.</span><span> </span><span class="NLM_article-title">Putative allosteric MEK1 and MEK2 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">â</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1517%2F13543776.18.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=603-627&author=S.+Price&title=Putative+allosteric+MEK1+and+MEK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Putative allosteric MEK1 and MEK2 inhibitors</span></div><div class="casAuthors">Price, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-627</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Over the last decade, the pharmaceutical industry has invested significantly in efforts to identify novel inhibitors of the mitogen-activated protein kinases MEK1 and MEK2.  Unsurprisingly, several ATP-competitive inhibitors have been identified, but the discovery of allosteric inhibitors has been the main focus for the development of novel therapies.  A no. of allosteric MEK1 and MEK2 inhibitors have been reported to exhibit exquisite selectivity when profiled against large panels of kinases.  Of the eight MEK inhibitors that have entered the clinic, it is believed that the majority, if not all, bind allosterically.  Objective: This review focuses on the patenting activity concerning putative allosteric MEK inhibitors, and their progression into the clinic.  Method: An anal. of the putative allosteric MEK inhibitor patent estate from the first-use application for PD-098059 in 1996 through to Feb. 2008 was undertaken.  An evaluation and summary of such therapies that have entered the clinic are provided.  Conclusion: The overwhelming majority of patents filed that describe putative allosteric MEK inhibitors are based on a diarylamine scaffold.  The ubiquitous expression of MEK throughout the body, and its central role in the cell signaling pathway, will undoubtedly ensure that inhibitors continue to be progressed into the clinic over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrembLi7K41BrVg90H21EOLACvtfcHk0lhCPWprOQhgUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D&md5=0ae01171b408bcd941d692fe57ae57ae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DPutative%2520allosteric%2520MEK1%2520and%2520MEK2%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D603%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ohren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuffa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spessard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasemann, C. A.</span><span> </span><span class="NLM_article-title">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">â</span> <span class="NLM_lpage">1197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fnsmb859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=15543157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1192-1197&author=J.+F.+Ohrenauthor=H.+Chenauthor=A.+Pavlovskyauthor=C.+Whiteheadauthor=E.+Zhangauthor=P.+Kuffaauthor=C.+Yanauthor=P.+McConnellauthor=C.+Spessardauthor=C.+Banotaiauthor=W.+T.+Muellerauthor=A.+Delaneyauthor=C.+Omerauthor=J.+S.+Sebolt-Leopoldauthor=D.+T.+Dudleyauthor=I.+K.+Leungauthor=C.+Flammeauthor=J.+Warmusauthor=M.+Kaufmanauthor=S.+Barrettauthor=H.+Tecleauthor=C.+A.+Hasemann&title=Structures+of+human+MAP+kinase+kinase+1+%28MEK1%29+and+MEK2+describe+novel+noncompetitive+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span></div><div class="casAuthors">Ohren, Jeffrey F.; Chen, Huifen; Pavlovsky, Alexander; Whitehead, Christopher; Zhang, Erli; Kuffa, Peter; Yan, Chunhong; McConnell, Patrick; Spessard, Cindy; Banotai, Craig; Mueller, W. Thomas; Delaney, Amy; Omer, Charles; Sebolt-Leopold, Judith; Dudley, David T.; Leung, Iris K.; Flamme, Cathlin; Warmus, Joseph; Kaufman, Michael; Barrett, Stephen; Tecle, Haile; Hasemann, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MEK1 and MEK2 kinases are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK MAP kinase (MAPK) signaling pathway.  Approx. 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation.  Here, the authors present the x-ray crystal structures of human MEK1 and MEK2 kinases, each detd. as a ternary complex with MgATP and an inhibitor to a resoln. of 2.4 and 3.2 Ã, resp.  The structures revealed that MEK1 and MEK2 each had a unique inhibitor-binding pocket adjacent to the MgATP-binding site.  The presence of the potent inhibitors induced several conformational changes in the unphosphorylated MEK1 and MEK2 kinases that locked them into a closed but catalytically inactive species.  Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIY9begVVfW7Vg90H21EOLACvtfcHk0lhRPM7Y9YiJVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM&md5=79ebbc2e3a9cdd3fbecb8bb35ea9dba3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb859%26sid%3Dliteratum%253Aachs%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DWhitehead%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DSpessard%26aufirst%3DC.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DFlamme%26aufirst%3DC.%26aulast%3DWarmus%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DHasemann%26aufirst%3DC.%2BA.%26atitle%3DStructures%2520of%2520human%2520MAP%2520kinase%2520kinase%25201%2520%2528MEK1%2529%2520and%2520MEK2%2520describe%2520novel%2520noncompetitive%2520kinase%2520inhibition%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1192%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhood, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannarino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V. S.</span><span> </span><span class="NLM_article-title">Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2661</span><span class="NLM_x">â</span> <span class="NLM_lpage">2674</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi801898e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=2661-2674&author=T.+O.+Fischmannauthor=C.+K.+Smithauthor=T.+W.+Mayhoodauthor=J.+E.+Myersauthor=P.+Reichertauthor=A.+Mannarinoauthor=D.+Carrauthor=H.+Zhuauthor=J.+Wongauthor=R.+Yangauthor=H.+V.+Leauthor=V.+S.+Madison&title=Crystal+structures+of+MEK1+binary+and+ternary+complexes+with+nucleotides+and+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbi801898e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi801898e%26sid%3Dliteratum%253Aachs%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSmith%26aufirst%3DC.%2BK.%26aulast%3DMayhood%26aufirst%3DT.%2BW.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DReichert%26aufirst%3DP.%26aulast%3DMannarino%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DMadison%26aufirst%3DV.%2BS.%26atitle%3DCrystal%2520structures%2520of%2520MEK1%2520binary%2520and%2520ternary%2520complexes%2520with%2520nucleotides%2520and%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D2661%26epage%3D2674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmirski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moshinsky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhawar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bora, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques-OâHagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">â</span> <span class="NLM_lpage">229</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=226-229&author=H.+Tecleauthor=J.+Shaoauthor=Y.+Liauthor=M.+Kotheauthor=S.+Kazmirskiauthor=J.+Penzottiauthor=Y.-H.+Dingauthor=J.+Ohrenauthor=D.+Moshinskyauthor=R.+Coliauthor=N.+Jhawarauthor=E.+Boraauthor=S.+Jacques-O%E2%80%99Haganauthor=J.+Wu&title=Beyond+the+MEK-pocket%3A+Can+current+MEK+kinase+inhibitors+be+utilized+to+synthesize+novel+type+III+NCKIs%3F+Does+the+MEK-pocket+exist+in+kinases+other+than+MEK%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKazmirski%26aufirst%3DS.%26aulast%3DPenzotti%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DY.-H.%26aulast%3DOhren%26aufirst%3DJ.%26aulast%3DMoshinsky%26aufirst%3DD.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DJhawar%26aufirst%3DN.%26aulast%3DBora%26aufirst%3DE.%26aulast%3DJacques-O%25E2%2580%2599Hagan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DBeyond%2520the%2520MEK-pocket%253A%2520Can%2520current%2520MEK%2520kinase%2520inhibitors%2520be%2520utilized%2520to%2520synthesize%2520novel%2520type%2520III%2520NCKIs%253F%2520Does%2520the%2520MEK-pocket%2520exist%2520in%2520kinases%2520other%2520than%2520MEK%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D226%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Trujillo, J. I.</span><span> </span><span class="NLM_article-title">MEK Inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1045</span><span class="NLM_x">â</span> <span class="NLM_lpage">1069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1517%2F13543776.2011.577068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=21548849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns12ms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1045-1069&issue=7&author=J.+I.+Trujillo&title=MEK+Inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors: a patent review 2008 - 2010</span></div><div class="casAuthors">Trujillo, John I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1069</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MAPK/extracellular signal-regulated kinase (MEK) inhibitors target the Ras/Raf/MEK/ERK signaling pathway, which is important in cell growth, differentiation and development.  The pathway has been implicated in the progression of a variety of diseases, in particular cancer, as well as in immune and inflammatory diseases such as rheumatoid arthritis, organ transplant rejection, septic shock, asthma and viral infection.  Areas covered: A comprehensive review of the patent literature (2008 - 2010) covering MEK inhibitors and combinations thereof is provided in this paper.  Expert opinion: The first MEK inhibitor was described in the literature in 1995, and several companies are still active in the research and development of MEK inhibitors for various disease states.  The emerging role of MEK inhibitors in disease has prompted further investigations of this important target.  The combination of MEK inhibitors with other agents/therapies in the treatment of diseases, particularly cancer, is a key development in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Dlhu0B2Us7Vg90H21EOLACvtfcHk0lhRPM7Y9YiJVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns12ms7Y%253D&md5=bd41140872c9005e24c4cf5597a4493d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.577068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.577068%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26atitle%3DMEK%2520Inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D1045%26epage%3D1069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Politzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. S.</span><span> </span><span class="NLM_article-title">An overview of halogen bonding</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1007%2Fs00894-006-0154-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17013631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFantL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=305-311&author=P.+Politzerauthor=P.+Laneauthor=M.+C.+Conchaauthor=Y.+Maauthor=J.+S.+Murray&title=An+overview+of+halogen+bonding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of halogen bonding</span></div><div class="casAuthors">Politzer, Peter; Lane, Pat; Concha, Monica C.; Ma, Yuguang; Murray, Jane S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-311</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Halogen bonding (XB) is a type of noncovalent interaction between a halogen atom X in one mol. and a neg. site in another.  X can be chlorine, bromine or iodine.  The strength of the interaction increases in the order Cl < Br < I.  After a brief review of exptl. evidence relating to halogen bonding, we present an explanation for its occurrence in terms of a region of pos. electrostatic potential that is present on the outermost portions of some covalently-bonded halogen atoms.  The existence and magnitude of this pos. region, which we call the Ï-hole, depends upon the relative electron-attracting powers of X and the remainder of its mol., as well as the degree of sp hybridization of the s unshared electrons of X.  The high electronegativity of fluorine and its tendency to undergo significant sp hybridization account for its failure to halogen bond.  Some computed XB interaction energies are presented and discussed.  Mention is also made of the importance of halogen bonding in biol. systems and processes, and in crystal engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4jkNxRc08s7Vg90H21EOLACvtfcHk0ljNRuKRt8RNnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFantL0%253D&md5=8d75bb2014ec661e2b1b657fff41e821</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00894-006-0154-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-006-0154-7%26sid%3Dliteratum%253Aachs%26aulast%3DPolitzer%26aufirst%3DP.%26aulast%3DLane%26aufirst%3DP.%26aulast%3DConcha%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520overview%2520of%2520halogen%2520bonding%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2007%26volume%3D13%26spage%3D305%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Voth, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. S.</span><span> </span><span class="NLM_article-title">The role of halogen bonding in inhibitor recognition and binding by protein kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1336</span><span class="NLM_x">â</span> <span class="NLM_lpage">1348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.2174%2F156802607781696846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17692024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1336-1348&author=A.+R.+Vothauthor=P.+S.+Ho&title=The+role+of+halogen+bonding+in+inhibitor+recognition+and+binding+by+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of halogen bonding in inhibitor recognition and binding by protein kinases</span></div><div class="casAuthors">Voth, Andrea Regier; Ho, P. Shing</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1336-1348</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Halogen bonds are short-range mol. interactions that are analogous to classical hydrogen bonds, except that a polarized halogen replaces the hydrogen as the acid in the Lewis acid/base pair.  Such interactions occur regularly in the structures of many ligand-protein complexes, but have only recently been recognized in biol. systems as a distinct class with well-defined phys. characteristics.  In this review, we survey twelve single crystal structures of protein kinase complexes with halogenated ligands in order to characterize the role of halogen bonds in conferring specificity and affinity for halogenated inhibitors in this important class of enzymes.  From this survey, we attempt to identify the properties of halogen bonds that can be generally applied to bottom-up strategies for designing inhibitors for this and other enzyme targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0lKs3fgdLV7Vg90H21EOLACvtfcHk0ljNRuKRt8RNnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrJ&md5=da1c1d603db9c2d93682f428198f0515</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156802607781696846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696846%26sid%3Dliteratum%253Aachs%26aulast%3DVoth%26aufirst%3DA.%2BR.%26aulast%3DHo%26aufirst%3DP.%2BS.%26atitle%3DThe%2520role%2520of%2520halogen%2520bonding%2520in%2520inhibitor%2520recognition%2520and%2520binding%2520by%2520protein%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1336%26epage%3D1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Iverson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, L.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dadson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarten, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span> </span><span class="NLM_article-title">RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6839</span><span class="NLM_x">â</span> <span class="NLM_lpage">6847</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6839-6847&author=C.+Iversonauthor=G.+Larsonauthor=C.+Laiauthor=L.-T.+Yehauthor=C.+Dadsonauthor=P.+Weingartenauthor=T.+Applebyauthor=T.+Voauthor=A.+Madernaauthor=J.+M.+Vernierauthor=R.+Hamatakeauthor=J.+N.+Minerauthor=B.+Quart&title=RDEA119%2FBAY+869766%3A+A+potent%2C+selective%2C+allosteric+inhibitor+of+MEK1%2F2+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIverson%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYeh%26aufirst%3DL.-T.%26aulast%3DDadson%26aufirst%3DC.%26aulast%3DWeingarten%26aufirst%3DP.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DVo%26aufirst%3DT.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26aulast%3DQuart%26aufirst%3DB.%26atitle%3DRDEA119%252FBAY%2520869766%253A%2520A%2520potent%252C%2520selective%252C%2520allosteric%2520inhibitor%2520of%2520MEK1%252F2%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6839%26epage%3D6847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Laurence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Questel, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renault, E.</span><span> </span><span class="NLM_article-title">The p<i>K</i><sub>BHX</sub> database: toward a better understanding of hydrogen-bond basicity for medicinal chemists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4073</span><span class="NLM_x">â</span> <span class="NLM_lpage">4086</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.+Y.+Le+Questelauthor=E.+Renault&title=The+pKBHX+database%3A+toward+a+better+understanding+of+hydrogen-bond+basicity+for+medicinal+chemists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0ljNRuKRt8RNnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.%2BY.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pKBHX%2520database%253A%2520toward%2520a%2520better%2520understanding%2520of%2520hydrogen-bond%2520basicity%2520for%2520medicinal%2520chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wallace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hingorani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span> </span><span class="NLM_article-title">Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050834y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=441-444&author=E.+M.+Wallaceauthor=J.+Lyssikatosauthor=J.+F.+Blakeauthor=J.+Seoauthor=H.+W.+Yangauthor=T.+C.+Yehauthor=M.+Perrierauthor=H.+Jarskiauthor=V.+Marshauthor=G.+Pochauthor=M.+G.+Livingstonauthor=J.+Ottenauthor=G.+Hingoraniauthor=R.+Woessnerauthor=P.+Leeauthor=J.+Winklerauthor=K.+Koch&title=Potent+and+selective+mitogen-activated+protein+kinase+kinase+%28MEK%29+1%2C2+inhibitors.+1.+4-%284-Bromo-2-fluorophenylamino%29-1-methylpyridin-2%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm050834y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050834y%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DPerrier%26aufirst%3DM.%26aulast%3DJarski%26aufirst%3DH.%26aulast%3DMarsh%26aufirst%3DV.%26aulast%3DPoch%26aufirst%3DG.%26aulast%3DLivingston%26aufirst%3DM.%2BG.%26aulast%3DOtten%26aufirst%3DJ.%26aulast%3DHingorani%26aufirst%3DG.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DKoch%26aufirst%3DK.%26atitle%3DPotent%2520and%2520selective%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520%2528MEK%2529%25201%252C2%2520inhibitors.%25201.%25204-%25284-Bromo-2-fluorophenylamino%2529-1-methylpyridin-2%25281H%2529-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D441%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Price, S.; Williams, K.; Savy, P. P.; Dyke, H. J.; Montana, J. G.; Stanley, M. S.; Bao, L.</span><span> </span><span class="NLM_article-title">Aza-benzofuranyl compounds and methods of use</span>. Patent WO2008024725,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Price&author=K.+Williams&author=P.+P.+Savy&author=H.+J.+Dyke&author=J.+G.+Montana&author=M.+S.+Stanley&author=L.+Bao&title=Aza-benzofuranyl+compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DAza-benzofuranyl%2520compounds%2520and%2520methods%2520of%2520use%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span> </span><span class="NLM_article-title">Preclinical disposition and pharmacokineticsâpharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">762</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=751-762&author=E.+F.+Chooauthor=M.+Belvinauthor=J.+Chanauthor=K.+Hoeflichauthor=C.+Orrauthor=K.+Robargeauthor=X.+Yangauthor=M.+Zakauthor=J.+Boggs&title=Preclinical+disposition+and+pharmacokinetics%E2%80%93pharmacodynamic+modeling+of+biomarker+response+and+tumour+growth+inhibition+in+xenograft+mouse+models+of+G-573%2C+a+MEK+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DHoeflich%26aufirst%3DK.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DBoggs%26aufirst%3DJ.%26atitle%3DPreclinical%2520disposition%2520and%2520pharmacokinetics%25E2%2580%2593pharmacodynamic%2520modeling%2520of%2520biomarker%2520response%2520and%2520tumour%2520growth%2520inhibition%2520in%2520xenograft%2520mouse%2520models%2520of%2520G-573%252C%2520a%2520MEK%2520inhibitor%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D11%26spage%3D751%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandretto, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span> </span><span class="NLM_article-title">Kinase inhibitors and the case for CH...O hydrogen bonds in proteinâligand binding</span> <span class="citation_source-journal">Proteins</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=567-576&author=A.+C.+Pierceauthor=K.+L.+Sandrettoauthor=G.+W.+Bemis&title=Kinase+inhibitors+and+the+case+for+CH...O+hydrogen+bonds+in+protein%E2%80%93ligand+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DSandretto%26aufirst%3DK.%2BL.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DKinase%2520inhibitors%2520and%2520the%2520case%2520for%2520CH...O%2520hydrogen%2520bonds%2520in%2520protein%25E2%2580%2593ligand%2520binding%26jtitle%3DProteins%26date%3D2002%26volume%3D49%26spage%3D567%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Toth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, S. G..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, G.</span><span> </span><span class="NLM_article-title">The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3476</span><span class="NLM_x">â</span> <span class="NLM_lpage">3493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.2174%2F138161207782794284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18220785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3476-3493&author=G.+Tothauthor=S.+G..+Bowersauthor=A.+P.+Truongauthor=G.+Probst&title=The+role+and+significance+of+unconventional+hydrogen+bonds+in+small+molecule+recognition+by+biological+receptors+of+pharmaceutical+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance</span></div><div class="casAuthors">Toth, Gergely; Bowers, Simeon G.; Truong, Anh P.; Probst, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3476-3493</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery and optimization of nonbonded interactions, such as van der Waals interactions, hydrogen bonds, salt bridges and the hydrophobic effect, between small mol. ligands and their receptors is one of the main challenges in rational drug discovery.  As the theory of mol. interactions advances more evidence accumulates that nonbonded interactions, such as unconventional hydrogen bonds (X-HÂ·Â·Â·Y interactions, where X can be either C, N or O atom and Y can be either an arom. ring system, O or F atom), contribute to ligand recognition by biol. receptors.  This review provides an overview of unconventional hydrogen bonds between ligands and their receptors of pharmaceutical relevance by dissecting their structure activity relationships and 3D structural elements.  Gaining an understanding of the energetic and the structural properties of unconventional hydrogen bonds in ligand-receptor interactions leads us to the elucidation of their practical significance.  Ultimately, this enables us to consciously apply these interactions in hit and lead optimization in rational structure based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOm79X4bmpLrVg90H21EOLACvtfcHk0lgJUyKtTmcyuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs73E&md5=543b57cfacc29b0389740eea1ab60b73</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138161207782794284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207782794284%26sid%3Dliteratum%253Aachs%26aulast%3DToth%26aufirst%3DG.%26aulast%3DBowers%26aufirst%3DS.%2BG..%26aulast%3DTruong%26aufirst%3DA.%2BP.%26aulast%3DProbst%26aufirst%3DG.%26atitle%3DThe%2520role%2520and%2520significance%2520of%2520unconventional%2520hydrogen%2520bonds%2520in%2520small%2520molecule%2520recognition%2520by%2520biological%2520receptors%2520of%2520pharmaceutical%2520relevance%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D3476%26epage%3D3493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Fink, D. M.; Strupczewski, J. T.</span><span> </span><span class="NLM_article-title">Process and intermediates for the preparation of 6-fluorobenzoisothiazoles</span>. Can. Pat. Appl. CA 2076556,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=D.+M.+Fink&author=J.+T.+Strupczewski&title=Process+and+intermediates+for+the+preparation+of+6-fluorobenzoisothiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFink%26aufirst%3DD.%2BM.%26atitle%3DProcess%2520and%2520intermediates%2520for%2520the%2520preparation%2520of%25206-fluorobenzoisothiazoles%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">â</span> <span class="NLM_lpage">1749</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Ã in nearly half of the cases and are greater than 2 Ã in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lgJUyKtTmcyuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+Diffraction+Data+Collected+in+Oscillation+Mode"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (Ï2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Ã unit cell to rotavirus of 700 Ã diam. crystd. in 700 Ã 1000 Ã 1400 Ã cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0liMOaYZlsRHNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography Collaborative Computational Project, Number 4</span>.  <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">D50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">763</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+programs+for+protein+crystallography+Collaborative+Computational+Project%2C+Number+4.+Acta+Crystallogr.%2C+Sect.+D%3A+Biol.+Crystallogr.+1994%2C+D50%2C+760%E2%80%93763%3B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%2520Collaborative%2520Computational%2520Project%252C%2520Number%25204%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3DD50%26spage%3D760%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an Automated Program for Molecular Replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">â</span> <span class="NLM_lpage">1025</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+Automated+Program+for+Molecular+Replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0liMOaYZlsRHNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520Automated%2520Program%2520for%2520Molecular%2520Replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xingye Chen, Haichun Liu, Wuchen Xie, Yan Yang, Yuchen Wang, Yuanrong Fan, Yi Hua, Lu Zhu, Junnan Zhao, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yanmin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5244-5262. <a href="https://doi.org/10.1021/acs.jcim.9b00684" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DInvestigation%252Bof%252BCrystal%252BStructures%252Bin%252BStructure-Based%252BVirtual%252BScreening%252Bfor%252BProtein%252BKinase%252BInhibitors%26aulast%3DChen%26aufirst%3DXingye%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17082019%26date%3D15112019%26date%3D05112019%26volume%3D59%26issue%3D12%26spage%3D5244%26epage%3D5262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Xiang</span>, <span class="hlFld-ContribAuthor ">Lin  He</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Taijin  Wang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyao  Yi</span>, <span class="hlFld-ContribAuthor ">Hairong  Wang</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Li  Zheng</span>, <span class="hlFld-ContribAuthor ">Lei  Lei</span>, <span class="hlFld-ContribAuthor ">Xiaobin  Li</span>, <span class="hlFld-ContribAuthor ">Hang  Song</span>, and <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (11)
                                     , 5488-5504. <a href="https://doi.org/10.1021/acs.jmedchem.6b00579" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00579%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BPurine-Based%252BHydroxamic%252BAcid%252BDerivatives%25253A%252BPotent%252BHistone%252BDeacetylase%252BInhibitors%252Bwith%252BMarked%252Bin%252BVitro%252Band%252Bin%252BVivo%252BAntitumor%252BActivities%26aulast%3DChen%26aufirst%3DYong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15042016%26date%3D24052016%26date%3D09062016%26date%3D17052016%26volume%3D59%26issue%3D11%26spage%3D5488%26epage%3D5504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert G.  Poston</span>, <span class="hlFld-ContribAuthor ">Lillian  Murphy</span>, <span class="hlFld-ContribAuthor ">Ayna  Rejepova</span>, <span class="hlFld-ContribAuthor ">Mina  Ghaninejad-Esfahani</span>, <span class="hlFld-ContribAuthor ">Joshua  Segales</span>, <span class="hlFld-ContribAuthor ">Kimberly  Mulligan</span>, <span class="hlFld-ContribAuthor ">Ramendra N.  Saha</span>. </span><span class="cited-content_cbyCitation_article-title">Certain ortho-hydroxylated brominated ethers are promiscuous kinase inhibitors that impair neuronal signaling and neurodevelopmental processes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (18)
                                     , 6120-6137. <a href="https://doi.org/10.1074/jbc.RA119.011138" title="DOI URL">https://doi.org/10.1074/jbc.RA119.011138</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.011138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.011138%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DCertain%252Bortho-hydroxylated%252Bbrominated%252Bethers%252Bare%252Bpromiscuous%252Bkinase%252Binhibitors%252Bthat%252Bimpair%252Bneuronal%252Bsignaling%252Band%252Bneurodevelopmental%252Bprocesses%26aulast%3DPoston%26aufirst%3DRobert%2BG.%26date%3D2020%26volume%3D295%26issue%3D18%26spage%3D6120%26epage%3D6137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Xi</span>, <span class="hlFld-ContribAuthor ">Yan  Niu</span>, <span class="hlFld-ContribAuthor ">Hongyue  Li</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Noha</span>, <span class="hlFld-ContribAuthor ">Veronika  Temml</span>, <span class="hlFld-ContribAuthor ">Daniela  Schuster</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Fengrong  Xu</span>, <span class="hlFld-ContribAuthor ">Ping  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 802-817. <a href="https://doi.org/10.1016/j.ejmech.2019.06.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bcarbazole%252Bderivatives%252Bas%252Bnovel%252Ballosteric%252BMEK%252Binhibitors%252Bby%252Bpharmacophore%252Bmodeling%252Band%252Bvirtual%252Bscreening%26aulast%3DXi%26aufirst%3DDandan%26date%3D2019%26volume%3D178%26spage%3D802%26epage%3D817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suravi  Chakrabarty</span>, <span class="hlFld-ContribAuthor ">Darlene A.  Monlish</span>, <span class="hlFld-ContribAuthor ">Mohit  Gupta</span>, <span class="hlFld-ContribAuthor ">Thomas D.  Wright</span>, <span class="hlFld-ContribAuthor ">Van T.  Hoang</span>, <span class="hlFld-ContribAuthor ">Mitchel  Fedak</span>, <span class="hlFld-ContribAuthor ">Ishveen  Chopra</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Flaherty</span>, <span class="hlFld-ContribAuthor ">Jeffry  Madura</span>, <span class="hlFld-ContribAuthor ">Shankar  Mannepelli</span>, <span class="hlFld-ContribAuthor ">Matthew E.  Burow</span>, <span class="hlFld-ContribAuthor ">Jane E.  Cavanaugh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (13)
                                     , 2294-2301. <a href="https://doi.org/10.1016/j.bmcl.2018.05.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.05.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.05.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%252Bactivity%252Brelationships%252Bof%252Banthranilic%252Bacid-based%252Bcompounds%252Bon%252Bcellular%252Band%252Bin%252Bvivo%252Bmitogen%252Bactivated%252Bprotein%252Bkinase-5%252Bsignaling%252Bpathways%26aulast%3DChakrabarty%26aufirst%3DSuravi%26date%3D2018%26volume%3D28%26issue%3D13%26spage%3D2294%26epage%3D2301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangxia  Zou</span>, <span class="hlFld-ContribAuthor ">Yifei  Yang</span>, <span class="hlFld-ContribAuthor ">Tianfang  Ma</span>, <span class="hlFld-ContribAuthor ">Jiayue  Xi</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Zha</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel MEK1 inhibitors by pharmacophore and docking based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (4)
                                     , 701-713. <a href="https://doi.org/10.1007/s00044-017-1788-y" title="DOI URL">https://doi.org/10.1007/s00044-017-1788-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-017-1788-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-017-1788-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DIdentification%252Bof%252Bnovel%252BMEK1%252Binhibitors%252Bby%252Bpharmacophore%252Band%252Bdocking%252Bbased%252Bvirtual%252Bscreening%26aulast%3DZou%26aufirst%3DFangxia%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D4%26spage%3D701%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 245-361. <a href="https://doi.org/10.1016/bs.aihch.2016.11.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BSynopsis%252Bof%252Bthe%252BProperties%252Band%252BApplications%252Bof%252BHeteroaromatic%252BRings%252Bin%252BMedicinal%252BChemistry%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D245%26epage%3D361%26pub%3DElsevier%26date%3D2017%26volume%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jialin  Shang</span>, <span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>, <span class="hlFld-ContribAuthor ">Yongjun  Jiang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric modulators of MEK1: drug design and discovery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>88 </em>
                                    (4)
                                     , 485-497. <a href="https://doi.org/10.1111/cbdd.12780" title="DOI URL">https://doi.org/10.1111/cbdd.12780</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12780%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DAllosteric%252Bmodulators%252Bof%252BMEK1%25253A%252Bdrug%252Bdesign%252Band%252Bdiscovery%26aulast%3DShang%26aufirst%3DJialin%26date%3D2016%26date%3D2016%26volume%3D88%26issue%3D4%26spage%3D485%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewen  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Liang</span>, <span class="hlFld-ContribAuthor ">Jianghong  Dong</span>, <span class="hlFld-ContribAuthor ">Zhiyuan  Fang</span>, <span class="hlFld-ContribAuthor ">Lingwen  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Lateral flow biosensor for multiplex detection of nitrofuran metabolites based on functionalized magnetic beads. </span><span class="cited-content_cbyCitation_journal-name">Analytical and Bioanalytical Chemistry</span><span> <strong>2016,</strong> <em>408 </em>
                                    (24)
                                     , 6703-6709. <a href="https://doi.org/10.1007/s00216-016-9787-2" title="DOI URL">https://doi.org/10.1007/s00216-016-9787-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00216-016-9787-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00216-016-9787-2%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520and%2520Bioanalytical%2520Chemistry%26atitle%3DLateral%252Bflow%252Bbiosensor%252Bfor%252Bmultiplex%252Bdetection%252Bof%252Bnitrofuran%252Bmetabolites%252Bbased%252Bon%252Bfunctionalized%252Bmagnetic%252Bbeads%26aulast%3DLu%26aufirst%3DXuewen%26date%3D2016%26date%3D2016%26volume%3D408%26issue%3D24%26spage%3D6703%26epage%3D6709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ingo V.  Hartung</span>, <span class="hlFld-ContribAuthor ">Florian  PÃ¼hler</span>, <span class="hlFld-ContribAuthor ">Roland  Neuhaus</span>, <span class="hlFld-ContribAuthor ">Arne  Scholz</span>, <span class="hlFld-ContribAuthor ">Gerhard  Siemeister</span>, <span class="hlFld-ContribAuthor ">Jens  Geisler</span>, <span class="hlFld-ContribAuthor ">Roman C.  Hillig</span>, <span class="hlFld-ContribAuthor ">Oliver  vonâAhsen</span>, <span class="hlFld-ContribAuthor ">Marion  Hitchcock</span>. </span><span class="cited-content_cbyCitation_article-title">Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2015,</strong> <em>10 </em>
                                    (12)
                                     , 2004-2013. <a href="https://doi.org/10.1002/cmdc.201500442" title="DOI URL">https://doi.org/10.1002/cmdc.201500442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500442%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DModular%252BAssembly%252Bof%252BAllosteric%252BMEK%252BInhibitor%252BStructural%252BElements%252BUnravels%252BPotency%252Band%252BFeedback-Modulation%252BHandles%26aulast%3DHartung%26aufirst%3DIngo%2BV.%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D12%26spage%3D2004%26epage%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul G.  Wylie</span>, <span class="hlFld-ContribAuthor ">David J.  Onley</span>, <span class="hlFld-ContribAuthor ">Anne F.  Hammerstein</span>, <span class="hlFld-ContribAuthor ">Wayne P.  Bowen</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Laser Scanning Imaging Cytometry for High-Content Screening. </span><span class="cited-content_cbyCitation_journal-name">ASSAY and Drug Development Technologies</span><span> <strong>2015,</strong> <em>13 </em>
                                    (2)
                                     , 66-78. <a href="https://doi.org/10.1089/adt.2014.607" title="DOI URL">https://doi.org/10.1089/adt.2014.607</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/adt.2014.607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fadt.2014.607%26sid%3Dliteratum%253Aachs%26jtitle%3DASSAY%2520and%2520Drug%2520Development%2520Technologies%26atitle%3DAdvances%252Bin%252BLaser%252BScanning%252BImaging%252BCytometry%252Bfor%252BHigh-Content%252BScreening%26aulast%3DWylie%26aufirst%3DPaul%2BG.%26date%3D2015%26volume%3D13%26issue%3D2%26spage%3D66%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jason J.  Luke</span>, <span class="hlFld-ContribAuthor ">Patrick A.  Ott</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>. </span><span class="cited-content_cbyCitation_article-title">The Biology and Clinical Development of MEK Inhibitors for Cancer. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2014,</strong> <em>74 </em>
                                    (18)
                                     , 2111-2128. <a href="https://doi.org/10.1007/s40265-014-0315-4" title="DOI URL">https://doi.org/10.1007/s40265-014-0315-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-014-0315-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-014-0315-4%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DThe%252BBiology%252Band%252BClinical%252BDevelopment%252Bof%252BMEK%252BInhibitors%252Bfor%252BCancer%26aulast%3DLuke%26aufirst%3DJason%2BJ.%26date%3D2014%26date%3D2014%26volume%3D74%26issue%3D18%26spage%3D2111%26epage%3D2128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kirk D.  Robarge</span>, <span class="hlFld-ContribAuthor ">Wendy  Lee</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Christian  Wiesmann</span>, <span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Steve  Price</span>, <span class="hlFld-ContribAuthor ">Joanne  Hewitt</span>, <span class="hlFld-ContribAuthor ">Philip  Jackson</span>, <span class="hlFld-ContribAuthor ">Pascal  Savy</span>, <span class="hlFld-ContribAuthor ">Brenda  Burton</span>, <span class="hlFld-ContribAuthor ">Edna F.  Choo</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Jason  Boggs</span>, <span class="hlFld-ContribAuthor ">April  Yang</span>, <span class="hlFld-ContribAuthor ">Xioaye  Yang</span>, <span class="hlFld-ContribAuthor ">Matthew  Baumgardner</span>. </span><span class="cited-content_cbyCitation_article-title">Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (19)
                                     , 4714-4723. <a href="https://doi.org/10.1016/j.bmcl.2014.08.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.08.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.08.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%252Bbased%252Bdesign%252Bof%252Bnovel%252B6%25252C5%252Bheterobicyclic%252Bmitogen-activated%252Bprotein%252Bkinase%252Bkinase%252B%252528MEK%252529%252Binhibitors%252Bleading%252Bto%252Bthe%252Bdiscovery%252Bof%252Bimidazo%25255B1%25252C5-a%25255D%252Bpyrazine%252BG-479%26aulast%3DRobarge%26aufirst%3DKirk%2BD.%26date%3D2014%26volume%3D24%26issue%3D19%26spage%3D4714%26epage%3D4723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samir  Mehndiratta</span>, <span class="hlFld-ContribAuthor ">Yi-Fang  Chiang</span>, <span class="hlFld-ContribAuthor ">Mei-Jung  Lai</span>, <span class="hlFld-ContribAuthor ">Hsueh-Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Chen</span>, <span class="hlFld-ContribAuthor ">Ching-Chuan  Kuo</span>, <span class="hlFld-ContribAuthor ">Chi-Yen  Chang</span>, <span class="hlFld-ContribAuthor ">Jang-Yang  Chang</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (17)
                                     , 4917-4923. <a href="https://doi.org/10.1016/j.bmc.2014.06.042" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.06.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.06.042%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DConcise%252Bsyntheses%252Bof%252B7-anilino-indoline-N-benzenesulfonamides%252Bas%252Bantimitotic%252Band%252Bvascular%252Bdisrupting%252Bagents%26aulast%3DMehndiratta%26aufirst%3DSamir%26date%3D2014%26volume%3D22%26issue%3D17%26spage%3D4917%26epage%3D4923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yusuke  Narita</span>, <span class="hlFld-ContribAuthor ">Kiyoshi  Okamoto</span>, <span class="hlFld-ContribAuthor ">Megumi Ikemori  Kawada</span>, <span class="hlFld-ContribAuthor ">Kazuma  Takase</span>, <span class="hlFld-ContribAuthor ">Yukinori  Minoshima</span>, <span class="hlFld-ContribAuthor ">Kotaro  Kodama</span>, <span class="hlFld-ContribAuthor ">Masao  Iwata</span>, <span class="hlFld-ContribAuthor ">Norimasa  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Kohei  Sawada</span>. </span><span class="cited-content_cbyCitation_article-title">Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2014,</strong> <em>13 </em>
                                    (4)
                                     , 823-832. <a href="https://doi.org/10.1158/1535-7163.MCT-13-0667" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-13-0667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-13-0667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-13-0667%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DNovel%252BATP-Competitive%252BMEK%252BInhibitor%252BE6201%252BIs%252BEffective%252Bagainst%252BVemurafenib-Resistant%252BMelanoma%252BHarboring%252Bthe%252BMEK1-C121S%252BMutation%252Bin%252Ba%252BPreclinical%252BModel%26aulast%3DNarita%26aufirst%3DYusuke%26date%3D2014%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D823%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra W  Cowan-Jacob</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Jahnke</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (5)
                                     , 541-561. <a href="https://doi.org/10.4155/fmc.13.216" title="DOI URL">https://doi.org/10.4155/fmc.13.216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.13.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.13.216%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bapproaches%252Bfor%252Btargeting%252Bkinases%25253A%252Ballosteric%252Binhibition%25252C%252Ballosteric%252Bactivation%252Band%252Bpseudokinases%26aulast%3DCowan-Jacob%26aufirst%3DSandra%2BW%26date%3D2014%26volume%3D6%26issue%3D5%26spage%3D541%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul N.  Mortenson</span>, <span class="hlFld-ContribAuthor ">Valerio  Berdini</span>, <span class="hlFld-ContribAuthor ">Marc  OâReilly</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Approaches to the Discovery of Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 69-92. <a href="https://doi.org/10.1016/B978-0-12-397918-6.00003-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-397918-6.00003-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-397918-6.00003-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-397918-6.00003-3%26sid%3Dliteratum%253Aachs%26atitle%3DFragment-Based%252BApproaches%252Bto%252Bthe%252BDiscovery%252Bof%252BKinase%252BInhibitors%26aulast%3DMortenson%26aufirst%3DPaul%2BN.%26date%3D2014%26spage%3D69%26epage%3D92%26pub%3DElsevier%26atitle%3DProtein%252BKinase%252BInhibitors%252Bin%252BResearch%252Band%252BMedicine%26date%3D2014%26volume%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed R.  Ali</span>, <span class="hlFld-ContribAuthor ">Eman R.  El-Bendary</span>, <span class="hlFld-ContribAuthor ">Mariam A.  Ghaly</span>, <span class="hlFld-ContribAuthor ">Ihsan A.  Shehata</span>. </span><span class="cited-content_cbyCitation_article-title">Novel acetamidothiazole derivatives: Synthesis and inÂ vitro anticancer evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>69 </em>, 908-919. <a href="https://doi.org/10.1016/j.ejmech.2013.08.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.08.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.08.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bacetamidothiazole%252Bderivatives%25253A%252BSynthesis%252Band%252Bin%2525C2%2525A0vitro%252Banticancer%252Bevaluation%26aulast%3DAli%26aufirst%3DAhmed%2BR.%26date%3D2013%26volume%3D69%26spage%3D908%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgia  Hatzivassiliou</span>, <span class="hlFld-ContribAuthor ">Jacob R.  Haling</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">Kyung  Song</span>, <span class="hlFld-ContribAuthor ">Steve  Price</span>, <span class="hlFld-ContribAuthor ">Robert  Heald</span>, <span class="hlFld-ContribAuthor ">Joanne F. M.  Hewitt</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Ariana  Peck</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Klaus P.  Hoeflich</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Shiuh-Ming  Luoh</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Anderson</span>, <span class="hlFld-ContribAuthor ">Mary J. C.  Ludlam</span>, <span class="hlFld-ContribAuthor ">Christian  Wiesmann</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2013,</strong> <em>501 </em>
                                    (7466)
                                     , 232-236. <a href="https://doi.org/10.1038/nature12441" title="DOI URL">https://doi.org/10.1038/nature12441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nature12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnature12441%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DMechanism%252Bof%252BMEK%252Binhibition%252Bdetermines%252Befficacy%252Bin%252Bmutant%252BKRAS-%252Bversus%252BBRAF-driven%252Bcancers%26aulast%3DHatzivassiliou%26aufirst%3DGeorgia%26date%3D2013%26date%3D2013%26volume%3D501%26issue%3D7466%26spage%3D232%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert E.  Martell</span>, <span class="hlFld-ContribAuthor ">David G.  Brooks</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Keith  Wilcoxen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Drugs for Promising Targets. </span><span class="cited-content_cbyCitation_journal-name">Clinical Therapeutics</span><span> <strong>2013,</strong> <em>35 </em>
                                    (9)
                                     , 1271-1281. <a href="https://doi.org/10.1016/j.clinthera.2013.08.005" title="DOI URL">https://doi.org/10.1016/j.clinthera.2013.08.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.clinthera.2013.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.clinthera.2013.08.005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Therapeutics%26atitle%3DDiscovery%252Bof%252BNovel%252BDrugs%252Bfor%252BPromising%252BTargets%26aulast%3DMartell%26aufirst%3DRobert%2BE.%26date%3D2013%26volume%3D35%26issue%3D9%26spage%3D1271%26epage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengrong  Xu</span>, <span class="hlFld-ContribAuthor ">Yan  Niu</span>, <span class="hlFld-ContribAuthor ">Yun  Wu</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Yihong  Peng</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Liang</span>, <span class="hlFld-ContribAuthor ">Ping  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted 3-Benzylcoumarins as Allosteric MEK1 Inhibitors: Design, Synthesis and Biological Evaluation as Antiviral Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2013,</strong> <em>18 </em>
                                    (5)
                                     , 6057-6091. <a href="https://doi.org/10.3390/molecules18056057" title="DOI URL">https://doi.org/10.3390/molecules18056057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules18056057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules18056057%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSubstituted%252B3-Benzylcoumarins%252Bas%252BAllosteric%252BMEK1%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bas%252BAntiviral%252BAgents%26aulast%3DWang%26aufirst%3DChao%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D5%26spage%3D6057%26epage%3D6091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ingo V.  Hartung</span>, <span class="hlFld-ContribAuthor ">Marion  Hitchcock</span>, <span class="hlFld-ContribAuthor ">Florian  PÃ¼hler</span>, <span class="hlFld-ContribAuthor ">Roland  Neuhaus</span>, <span class="hlFld-ContribAuthor ">Arne  Scholz</span>, <span class="hlFld-ContribAuthor ">Stefanie  Hammer</span>, <span class="hlFld-ContribAuthor ">Kirstin  Petersen</span>, <span class="hlFld-ContribAuthor ">Gerhard  Siemeister</span>, <span class="hlFld-ContribAuthor ">Dominic  Brittain</span>, <span class="hlFld-ContribAuthor ">Roman C.  Hillig</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (8)
                                     , 2384-2390. <a href="https://doi.org/10.1016/j.bmcl.2013.02.028" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.02.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.02.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252Ballosteric%252BMEK%252Binhibitors.%252BPart%252B1%25253A%252BVenturing%252Binto%252Bunderexplored%252BSAR%252Bterritories%26aulast%3DHartung%26aufirst%3DIngo%2BV.%26date%3D2013%26volume%3D23%26issue%3D8%26spage%3D2384%26epage%3D2390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lorenzo  Palmieri</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Î±C helix displacement as a general approach for allosteric modulation of protein kinases. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2013,</strong> <em>18 </em>
                                    (7-8)
                                     , 407-414. <a href="https://doi.org/10.1016/j.drudis.2012.11.009" title="DOI URL">https://doi.org/10.1016/j.drudis.2012.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2012.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2012.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3D%2525CE%2525B1C%252Bhelix%252Bdisplacement%252Bas%252Ba%252Bgeneral%252Bapproach%252Bfor%252Ballosteric%252Bmodulation%252Bof%252Bprotein%252Bkinases%26aulast%3DPalmieri%26aufirst%3DLorenzo%26date%3D2013%26volume%3D18%26issue%3D7-8%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steve  Wenglowsky</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[3,4-
              b
              ]pyridine kinase inhibitors: a patent review (2008 â present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (3)
                                     , 281-298. <a href="https://doi.org/10.1517/13543776.2013.749861" title="DOI URL">https://doi.org/10.1517/13543776.2013.749861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.749861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.749861%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPyrazolo%25255B3%25252C4-%252Bb%252B%25255Dpyridine%252Bkinase%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282008%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DWenglowsky%26aufirst%3DSteve%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D281%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew R.  Scholfield</span>, <span class="hlFld-ContribAuthor ">Crystal M. Vander  Zanden</span>, <span class="hlFld-ContribAuthor ">Megan  Carter</span>, <span class="hlFld-ContribAuthor ">P. Shing  Ho</span>. </span><span class="cited-content_cbyCitation_article-title">Halogen bonding (X-bonding): A biological perspective. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2013,</strong> <em>22 </em>
                                    (2)
                                     , 139-152. <a href="https://doi.org/10.1002/pro.2201" title="DOI URL">https://doi.org/10.1002/pro.2201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.2201%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DHalogen%252Bbonding%252B%252528X-bonding%252529%25253A%252BA%252Bbiological%252Bperspective%26aulast%3DScholfield%26aufirst%3DMatthew%2BR.%26date%3D2013%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D139%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of designed analogue <b>1</b> with <b>2</b>, <b>3</b>, and <b>4</b>. âAâ and âBâ rings of <b>2</b> are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The key interactions of biarylaniline MEK inhibitors: crystal structure of MEK1 in complex with ATP (green) and PD318088 (orange) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1S9J">1S9J</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Overlay between the docked pose of <b>1</b> (orange) and the crystal structure of <b>3</b> (cyan, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V01">3V01</a>). (B) Overlay between <b>1</b> manually adjusted in the binding site (orange) and the crystal structure of <b>3</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Indazole Analogues <b>1</b> and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (COCl)<sub>2</sub>, DMF, DCM, (ii) tBuOH, pyridine, DCM; (b) (i) LDA, THF, (ii) DMF; (c) N<sub>2</sub>H<sub>4</sub>Â·H<sub>2</sub>O DME, 90 Â°C; (d) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM; (e) Pd<sub>2</sub>dba<sub>3</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, toluene, 90 Â°C; (f) (i) ICl, DCM or NBS, DCM, (ii) TFA, DCM; (g) EDCI, DIPEA, HOBt, DMF; (h) MeOH, HCl.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>1</b> in complex with MEK1 (orange, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V04">3V04</a>); modeled hydrogens shown for clarity. For comparison, the crystal structure of MEK1 in complex with <b>3</b> is also shown (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy in HCT116 colorectal xenograft model. Mice were randomized and treated with vehicle or <b>1</b> at 5, 25, and 75 mg/kg or <b>4</b> at 5 mg/kg, orally (PO) every day (QD) for 3 weeks. \ = death or euthanasia: 2 animals in the vehicle treated group had tumor volume >2000 mm<sup>3</sup>; animals euthanized in the compound treated groups had body weight loss >20%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/medium/jm-2011-017094_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route to Benzoisothiazole Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm2017094/production/images/large/jm-2011-017094_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm2017094&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Boc<sub>2</sub>O, DMAP, tBuOH, 45 Â°C; (b) NBS, AIBN, CCl<sub>4</sub>, reflux; (c) trimethylamine oxide, DCM, DMSO, rt; (d) BnSH, tBuOK, THF, â30 Â°C; (e) (i) SOCl<sub>2</sub>, DCM, rt, (ii) NH<sub>3</sub>, MeOH, THF, rt; (f) LHMDS, THF, â78 Â°C; (g) TFA, DCM, rt; (h) RONH<sub>2</sub>, EDCI, HOBt, DIPEA, THF, rt; (i) HCl, MeOH, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">â</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lg5IF4utK_OGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hoshino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari-I, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohno, M.</span><span> </span><span class="NLM_article-title">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">â</span> <span class="NLM_lpage">822</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fsj.onc.1202367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=9989833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=813-822&author=R.+Hoshinoauthor=Y.+Chantaniauthor=T.+Yamoriauthor=T.+Tsuruoauthor=H.+Okaauthor=O.+Yoshidaauthor=Y.+Shimadaauthor=S.+Ari-Iauthor=H.+Wadaauthor=J.+Fujimotoauthor=M.+Kohno&title=Constitutive+activation+of+the+41-%2F43-kDa+mitogen-activated+protein+kinase+signaling+pathway+in+human+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors</span></div><div class="casAuthors">Hoshino, Rika; Chatani, Yuji; Yamori, Takao; Tsuruo, Takashi; Oka, Hiroya; Yoshida, Osamu; Shimada, Yutaka; Ari-i, Shigeki; Wada, Hiromi; Fujimoto, Jiro; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1.  As aberrant activation of signal transducing mols. such as Ras and Raf-1 has been linked with cancer, the authors examd. whether constitutive activation of the 41-/43-kDa MAP kinases is assocd. with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs.  Constitutive activation of the MAP kinases was obsd. in 50 tumor cell lines (36.2%) in a rather tissue-specific manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed esp. high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation.  The authors also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large no. of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue.  Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation.  In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely assocd. with the activation of MEK and p90rsk in all the tumor cells examd.  These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling mols. upstream of Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRICRJXnIoerVg90H21EOLACvtfcHk0lg5IF4utK_OGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1eht70%253D&md5=719a702e589f259a22f53f7a2be0e94a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202367%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DR.%26aulast%3DChantani%26aufirst%3DY.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DO.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAri-I%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DFujimoto%26aufirst%3DJ.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DConstitutive%2520activation%2520of%2520the%252041-%252F43-kDa%2520mitogen-activated%2520protein%2520kinase%2520signaling%2520pathway%2520in%2520human%2520tumors%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D813%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">â</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with â¼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0licaPAl4XLakw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span> </span><span class="NLM_article-title">Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3651</span><span class="NLM_x">â</span> <span class="NLM_lpage">3656</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-08-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18559577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlWkurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3651-3656&author=J.+S.+Sebolt-Leopold&title=Advances+in+the+development+of+cancer+therapeutics+directed+against+the+RAS-mitogen-activated+protein+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway</span></div><div class="casAuthors">Sebolt-Leopold, Judith S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3651-3656</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Among mammalian mitogen-activated protein kinase (MAPK) signaling cascades, the extracellular signal-related kinase (ERK) pathway has received the most attention in the oncol. drug discovery arena.  By virtue of its central role in promoting proliferation, survival, and metastasis, this pathway directly affects both the formation and progression of human tumors.  The identification of non-ATP-competitive inhibitors of the MAPK kinase MAPK/ERK kinase (MEK) resulted in the first demonstration that the ERK pathway could be effectively shut down in a highly selective fashion.  Subsequent discovery of the oncogenic nature of B-raf kinase led to the escalation of drug discovery efforts revolving around MEK and RAF.  The emergence of multiple drug candidates targeting these downstream kinases provides us with the means for validating the importance of the RAS-RAF-MEK-ERK signaling cascade in human tumors.  This article highlights the lessons learned in the clin. evaluation of MAPK pathway inhibitors as anticancer agents and the complexities surrounding optimization of their therapeutic potential in light of the challenges posed by genetic heterogeneity within patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGj-KF9xysMLVg90H21EOLACvtfcHk0licaPAl4XLakw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlWkurc%253D&md5=872292fa6eba2bc8f97fd454b947c53a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0333%26sid%3Dliteratum%253Aachs%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520cancer%2520therapeutics%2520directed%2520against%2520the%2520RAS-mitogen-activated%2520protein%2520kinase%2520pathway%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3651%26epage%3D3656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span>Thomson Reuters Integrity; <span class="NLM_publisher-name">Thomson Reuters</span>: <span class="NLM_publisher-loc">East Haven, CT</span>; <a href="http://integrity.prous.com/" class="extLink">http://integrity.prous.com/</a> (Accessed <span class="NLM_access-date">December 10, 2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Thomson+Reuters+Integrity%3B+Thomson+Reuters%3A+East+Haven%2C+CT%3B+http%3A%2F%2Fintegrity.prous.com%2F+%28Accessed+December+10%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThomson%2520Reuters%2520Integrity%26pub%3DThomson%2520Reuters" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">FrÃ©min, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloche, S.</span><span> </span><span class="NLM_article-title">From basic research to clinical development of MEK1/2 inhibitors for cancer therapy</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1186%2F1756-8722-3-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=20149254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ltFGnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=8&author=C.+Fr%C3%A9minauthor=S.+Meloche&title=From+basic+research+to+clinical+development+of+MEK1%2F2+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From basic research to clinical development of MEK1/2 inhibitors for cancer therapy</span></div><div class="casAuthors">Fremin Christophe; Meloche Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival.  Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes.  Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer.  In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway.  We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXiqh48Jb4JresJRIHUP1ofW6udTcc2ea1mQ3x7lG7M7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ltFGnsg%253D%253D&md5=b6b8c91b259b37885fd951001b4bd817</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-8%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9min%26aufirst%3DC.%26aulast%3DMeloche%26aufirst%3DS.%26atitle%3DFrom%2520basic%2520research%2520to%2520clinical%2520development%2520of%2520MEK1%252F2%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yeh, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernat, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, E.</span><span> </span><span class="NLM_article-title">Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1576</span><span class="NLM_x">â</span> <span class="NLM_lpage">1583</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-06-1150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17332304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1576-1583&author=T.+C.+Yehauthor=V.+Marshauthor=B.+A.+Bernatauthor=J.+Ballardauthor=H.+Colwellauthor=R.+J.+Evansauthor=J.+Parryauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+Grossauthor=A.+Marlowauthor=B.+Hurleyauthor=J.+Lyssikatosauthor=P.+A.+Leeauthor=J.+D.+Winklerauthor=K.+Kochauthor=E.+Wallace&title=Biological+characterization+of+ARRY-142886+%28AZD6244%29%2C+a+potent%2C+highly+selective+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Biological characterization of ARRY-142886 (AZD6244), a ptent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor</span></div><div class="casAuthors">Yeh, Tammie C.; Marsh, Vivienne; Bernat, Bryan A.; Ballard, Josh; Colwell, Heidi; Evans, Ron J.; Parry, Janet; Smith, Darin; Brandhuber, Barbara J.; Gross, Stefan; Marlow, Allison; Hurley, Brian; Lyssikatos, Joe; Lee, Patrice A.; Winkler, James D.; Koch, Kevin; Wallace, Eli</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1576-1583</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics.  We have developed a highly potent and selective inhibitor of MEK1/2.  The purpose of these studies has been to show the biol. efficacy of ARRY-142886 (AZD6244) in enzymic, cellular, and animal models.  The ability of ARRY-142886 to inhibit purified MEK1 as well as other kinases was evaluated.  Its effects on extracellular signal-regulated kinase (ERK) phosphorylation and proliferation in several cell lines were also detd.  Finally, the inhibitor was tested in HT-29 (colorectal) and BxPC3 (pancreatic) xenograft tumor models.  The IC50 of ARRY-142886 was detd. to be 14 nmol/L against purified MEK1.  This activity is not competitive with ATP, which is consistent with the high specificity of compd. for MEK1/2.  Basal and epidermal growth factor-induced ERK1/2 phosphorylation was inhibited in several cell lines as well as 12-O-tetradecanoylphorbol-13-acetate-induced ERK1/2 phosphorylation in isolated peripheral blood mononuclear cells.  Treatment with ARRY-142886 resulted in the growth inhibition of several cell lines contg. B-Raf and Ras mutations but had no effect on a normal fibroblast cell line.  When dosed orally, ARRY-142886 was capable of inhibiting both ERK1/2 phosphorylation and growth of HT-29 xenograft tumors in nude mice.  Tumor regressions were also seen in a BxPC3 xenograft model.  In addn., tumors remained responsive to growth inhibition after a 7-day dosing holiday.  ARRY-142886 is a potent and selective MEK1/2 inhibitor that is highly active in both in vitro and in vivo tumor models.  This compd. is currently being investigated in clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7qJbWopjHu7Vg90H21EOLACvtfcHk0licaPAl4XLakw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLg%253D&md5=677df690d8016a8b5ad44f46ad1ec027</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1150%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DMarsh%26aufirst%3DV.%26aulast%3DBernat%26aufirst%3DB.%2BA.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DColwell%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DParry%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DMarlow%26aufirst%3DA.%26aulast%3DHurley%26aufirst%3DB.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BA.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DKoch%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DE.%26atitle%3DBiological%2520characterization%2520of%2520ARRY-142886%2520%2528AZD6244%2529%252C%2520a%2520potent%252C%2520highly%2520selective%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1576%26epage%3D1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2209</span><span class="NLM_x">â</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+McKayauthor=P.+Martinauthor=S.+Steeleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+1%2F2+kinases%3A+mechanism+of+action+in+vivo%2C+pharmacokinetic%2Fpharmacodynamic+relationship%2C+and+potential+for+combination+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0lj7a8t6Ba0jmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMcKay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DSteele%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%25201%252F2%2520kinases%253A%2520mechanism%2520of%2520action%2520in%2520vivo%252C%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%252C%2520and%2520potential%2520for%2520combination%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2209%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlow, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litwiler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span> </span><span class="NLM_article-title">Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2139</span><span class="NLM_x">â</span> <span class="NLM_lpage">2146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1200%2FJCO.2007.14.4956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18390968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1OrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2139-2146&author=A.+A.+Adjeiauthor=R.+B.+Cohenauthor=W.+Franklinauthor=C.+Morrisauthor=D.+Wilsonauthor=J.+R.+Molinaauthor=L.+J.+Hansonauthor=L.+Goreauthor=L.+Chowauthor=S.+Leongauthor=L.+Maloneyauthor=G.+Gordonauthor=H.+Simmonsauthor=A.+Marlowauthor=K.+Litwilerauthor=S.+Brownauthor=G.+Pochauthor=K.+Kaneauthor=J.+Haneyauthor=S.+G.+Eckhardt&title=Phase+I+pharmacokinetic+and+pharmacodynamic+study+of+the+oral%2C+small-molecule+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor+AZD6244+%28ARRY-142886%29+in+patients+with+advanced+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers</span></div><div class="casAuthors">Adjei, Alex A.; Cohen, Roger B.; Franklin, Wilbur; Morris, Clive; Wilson, David; Molina, Julian R.; Hanson, Lorelei J.; Gore, Lia; Chow, Laura; Leong, Stephen; Maloney, Lara; Gordon, Gilad; Simmons, Heidi; Marlow, Allison; Litwiler, Kevin; Brown, Suzy; Poch, Gregory; Kane, Katie; Haney, Jerry; Eckhardt, S. Gail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2139-2146</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer.  In part A, patients received escalating doses to det. the max.-tolerated dose (MTD).  In both parts, blood samples were collected to assess PK and PD parameters.  In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to receive the MTD or 50% MTD.  Biopsies were collected to det. inhibition of ERK phosphorylation, Ki-67 expression, and BRAF, KRAS, and NRAS mutations.  Fifty-seven patients were enrolled.  MTD in part A was 200 mg bid, but this dose was discontinued in part B because of toxicity.  The 50% MTD (100 mg bid) was well tolerated.  Rash was the most frequent and dose-limiting toxicity.  Most other adverse events were grade 1 or 2.  The PKs were less than dose proportional, with a median half-life of approx. 8 h and inhibition of ERK phosphorylation in peripheral-blood mononuclear cells at all dose levels.  Paired tumor biopsies demonstrated, reduced ERK phosphorylation (geometric mean, 79%).  Five of 20 patients demonstrated â¥ 50% inhibition of Ki-67 expression, and RAF or RAS mutations were detected in 10 of 26 assessable tumor samples.  Nine patients had stable disease (SD) for â¥ 5 mo, including two patients with SD for 19 (thyroid cancer) and 22 (uveal melanoma plus renal cancer) 28-day cycles.  AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose.  PK analyses supported twice-daily dosing.  Prolonged SD was seen in a variety of advanced cancers.  Phase II studies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI2Uc-97FbNbVg90H21EOLACvtfcHk0lj7a8t6Ba0jmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1OrtL8%253D&md5=c6f68db45ff4788414ad556f3eaf2acc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.14.4956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.14.4956%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DFranklin%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DHanson%26aufirst%3DL.%2BJ.%26aulast%3DGore%26aufirst%3DL.%26aulast%3DChow%26aufirst%3DL.%26aulast%3DLeong%26aufirst%3DS.%26aulast%3DMaloney%26aufirst%3DL.%26aulast%3DGordon%26aufirst%3DG.%26aulast%3DSimmons%26aufirst%3DH.%26aulast%3DMarlow%26aufirst%3DA.%26aulast%3DLitwiler%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DS.%26aulast%3DPoch%26aufirst%3DG.%26aulast%3DKane%26aufirst%3DK.%26aulast%3DHaney%26aufirst%3DJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26atitle%3DPhase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%252C%2520small-molecule%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%2520AZD6244%2520%2528ARRY-142886%2529%2520in%2520patients%2520with%2520advanced%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2139%26epage%3D2146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Barrett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltiel, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fergus, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamme, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LePage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Przybranowski, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Becelaere, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, W. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span> </span><span class="NLM_article-title">The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD0325901</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6501</span><span class="NLM_x">â</span> <span class="NLM_lpage">6504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6501-6504&author=S.+D.+Barrettauthor=A.+J.+Bridgesauthor=D.+T.+Dudleyauthor=A.+R.+Saltielauthor=J.+H.+Fergusauthor=C.+M.+Flammeauthor=A.+M.+Delaneyauthor=M.+Kaufmanauthor=S.+LePageauthor=W.+R.+Leopoldauthor=S.+A.+Przybranowskiauthor=J.+Sebolt-Leopoldauthor=K.+Van+Becelaereauthor=A.+M.+Dohertyauthor=R.+M.+Kennedyauthor=D.+Marstonauthor=W.+A.+Howardauthor=Y.+Smithauthor=J.+S.+Warmusauthor=H.+Tecle&title=The+discovery+of+the+benzhydroxamate+MEK+inhibitors+CI-1040+and+PD0325901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarrett%26aufirst%3DS.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DSaltiel%26aufirst%3DA.%2BR.%26aulast%3DFergus%26aufirst%3DJ.%2BH.%26aulast%3DFlamme%26aufirst%3DC.%2BM.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DLePage%26aufirst%3DS.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DPrzybranowski%26aufirst%3DS.%2BA.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DKennedy%26aufirst%3DR.%2BM.%26aulast%3DMarston%26aufirst%3DD.%26aulast%3DHoward%26aufirst%3DW.%2BA.%26aulast%3DSmith%26aufirst%3DY.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DTecle%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520the%2520benzhydroxamate%2520MEK%2520inhibitors%2520CI-1040%2520and%2520PD0325901%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6501%26epage%3D6504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span>ClinicalTrials.gov; <span class="NLM_publisher-name">National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>; <a href="http://www.clinicaltrials.gov/ct2/results?term=AZD6244" class="extLink">http://www.clinicaltrials.gov/ct2/results?term=AZD6244</a> (Accessed <span class="NLM_access-date">December 10, 2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov%3B+National+Institutes+of+Health%3A+Bethesda%2C+MD%3B+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DAZD6244+%28Accessed+December+10%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DClinicalTrials.gov%26pub%3DNational%2520Institutes%2520of%2520Health" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Abe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inaba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakefuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurachi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakegawa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmartin, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">320</span><span class="NLM_x">â</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&issue=4&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+Highly+Potent+and+Selective+MEK+Inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+Solvate%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520MEK%2520Inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520Solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D4%26spage%3D320%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Januario, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punnoose, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span> </span><span class="NLM_article-title">In Vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4649</span><span class="NLM_x">â</span> <span class="NLM_lpage">4664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1158%2F1078-0432.CCR-09-0317" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=4649-4664&author=K.+P.+Hoeflichauthor=C.+O%E2%80%99Brienauthor=Z.+Boydauthor=G.+Cavetauthor=S.+Guerreroauthor=K.+Jungauthor=T.+Januarioauthor=H.+Savageauthor=E.+Punnooseauthor=T.+Truongauthor=W.+Zhouauthor=L.+Berryauthor=L.+Murrayauthor=L.+Amlerauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=M.+R.+Lackner&title=In+Vivo+Antitumor+Activity+of+MEK+and+Phosphatidylinositol+3-Kinase+Inhibitors+in+Basal-Like+Breast+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0317%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DBoyd%26aufirst%3DZ.%26aulast%3DCavet%26aufirst%3DG.%26aulast%3DGuerrero%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DK.%26aulast%3DJanuario%26aufirst%3DT.%26aulast%3DSavage%26aufirst%3DH.%26aulast%3DPunnoose%26aufirst%3DE.%26aulast%3DTruong%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DMurray%26aufirst%3DL.%26aulast%3DAmler%26aufirst%3DL.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26atitle%3DIn%2520Vivo%2520Antitumor%2520Activity%2520of%2520MEK%2520and%2520Phosphatidylinositol%25203-Kinase%2520Inhibitors%2520in%2520Basal-Like%2520Breast%2520Cancer%2520Models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D14%26spage%3D4649%26epage%3D4664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hatzivassiliou1, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliou1author=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+J.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou1%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BJ.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Price, S.</span><span> </span><span class="NLM_article-title">Putative allosteric MEK1 and MEK2 inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">â</span> <span class="NLM_lpage">627</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1517%2F13543776.18.6.603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=603-627&author=S.+Price&title=Putative+allosteric+MEK1+and+MEK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Putative allosteric MEK1 and MEK2 inhibitors</span></div><div class="casAuthors">Price, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-627</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Over the last decade, the pharmaceutical industry has invested significantly in efforts to identify novel inhibitors of the mitogen-activated protein kinases MEK1 and MEK2.  Unsurprisingly, several ATP-competitive inhibitors have been identified, but the discovery of allosteric inhibitors has been the main focus for the development of novel therapies.  A no. of allosteric MEK1 and MEK2 inhibitors have been reported to exhibit exquisite selectivity when profiled against large panels of kinases.  Of the eight MEK inhibitors that have entered the clinic, it is believed that the majority, if not all, bind allosterically.  Objective: This review focuses on the patenting activity concerning putative allosteric MEK inhibitors, and their progression into the clinic.  Method: An anal. of the putative allosteric MEK inhibitor patent estate from the first-use application for PD-098059 in 1996 through to Feb. 2008 was undertaken.  An evaluation and summary of such therapies that have entered the clinic are provided.  Conclusion: The overwhelming majority of patents filed that describe putative allosteric MEK inhibitors are based on a diarylamine scaffold.  The ubiquitous expression of MEK throughout the body, and its central role in the cell signaling pathway, will undoubtedly ensure that inhibitors continue to be progressed into the clinic over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrembLi7K41BrVg90H21EOLACvtfcHk0ljDm23H3QDugg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt74%253D&md5=0ae01171b408bcd941d692fe57ae57ae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DPutative%2520allosteric%2520MEK1%2520and%2520MEK2%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D603%26epage%3D627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ohren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuffa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spessard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasemann, C. A.</span><span> </span><span class="NLM_article-title">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span> <span class="citation_source-journal">Nature Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1192</span><span class="NLM_x">â</span> <span class="NLM_lpage">1197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1038%2Fnsmb859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=15543157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1192-1197&author=J.+F.+Ohrenauthor=H.+Chenauthor=A.+Pavlovskyauthor=C.+Whiteheadauthor=E.+Zhangauthor=P.+Kuffaauthor=C.+Yanauthor=P.+McConnellauthor=C.+Spessardauthor=C.+Banotaiauthor=W.+T.+Muellerauthor=A.+Delaneyauthor=C.+Omerauthor=J.+S.+Sebolt-Leopoldauthor=D.+T.+Dudleyauthor=I.+K.+Leungauthor=C.+Flammeauthor=J.+Warmusauthor=M.+Kaufmanauthor=S.+Barrettauthor=H.+Tecleauthor=C.+A.+Hasemann&title=Structures+of+human+MAP+kinase+kinase+1+%28MEK1%29+and+MEK2+describe+novel+noncompetitive+kinase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition</span></div><div class="casAuthors">Ohren, Jeffrey F.; Chen, Huifen; Pavlovsky, Alexander; Whitehead, Christopher; Zhang, Erli; Kuffa, Peter; Yan, Chunhong; McConnell, Patrick; Spessard, Cindy; Banotai, Craig; Mueller, W. Thomas; Delaney, Amy; Omer, Charles; Sebolt-Leopold, Judith; Dudley, David T.; Leung, Iris K.; Flamme, Cathlin; Warmus, Joseph; Kaufman, Michael; Barrett, Stephen; Tecle, Haile; Hasemann, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1192-1197</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MEK1 and MEK2 kinases are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK MAP kinase (MAPK) signaling pathway.  Approx. 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation.  Here, the authors present the x-ray crystal structures of human MEK1 and MEK2 kinases, each detd. as a ternary complex with MgATP and an inhibitor to a resoln. of 2.4 and 3.2 Ã, resp.  The structures revealed that MEK1 and MEK2 each had a unique inhibitor-binding pocket adjacent to the MgATP-binding site.  The presence of the potent inhibitors induced several conformational changes in the unphosphorylated MEK1 and MEK2 kinases that locked them into a closed but catalytically inactive species.  Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIY9begVVfW7Vg90H21EOLACvtfcHk0ljDm23H3QDugg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVens7jM&md5=79ebbc2e3a9cdd3fbecb8bb35ea9dba3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb859%26sid%3Dliteratum%253Aachs%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DWhitehead%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DE.%26aulast%3DKuffa%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DSpessard%26aufirst%3DC.%26aulast%3DBanotai%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DDelaney%26aufirst%3DA.%26aulast%3DOmer%26aufirst%3DC.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%2BS.%26aulast%3DDudley%26aufirst%3DD.%2BT.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DFlamme%26aufirst%3DC.%26aulast%3DWarmus%26aufirst%3DJ.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DS.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DHasemann%26aufirst%3DC.%2BA.%26atitle%3DStructures%2520of%2520human%2520MAP%2520kinase%2520kinase%25201%2520%2528MEK1%2529%2520and%2520MEK2%2520describe%2520novel%2520noncompetitive%2520kinase%2520inhibition%26jtitle%3DNature%2520Struct.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D1192%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhood, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannarino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V. S.</span><span> </span><span class="NLM_article-title">Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2661</span><span class="NLM_x">â</span> <span class="NLM_lpage">2674</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi801898e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=2661-2674&author=T.+O.+Fischmannauthor=C.+K.+Smithauthor=T.+W.+Mayhoodauthor=J.+E.+Myersauthor=P.+Reichertauthor=A.+Mannarinoauthor=D.+Carrauthor=H.+Zhuauthor=J.+Wongauthor=R.+Yangauthor=H.+V.+Leauthor=V.+S.+Madison&title=Crystal+structures+of+MEK1+binary+and+ternary+complexes+with+nucleotides+and+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fbi801898e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi801898e%26sid%3Dliteratum%253Aachs%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DSmith%26aufirst%3DC.%2BK.%26aulast%3DMayhood%26aufirst%3DT.%2BW.%26aulast%3DMyers%26aufirst%3DJ.%2BE.%26aulast%3DReichert%26aufirst%3DP.%26aulast%3DMannarino%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DMadison%26aufirst%3DV.%2BS.%26atitle%3DCrystal%2520structures%2520of%2520MEK1%2520binary%2520and%2520ternary%2520complexes%2520with%2520nucleotides%2520and%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D2661%26epage%3D2674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmirski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penzotti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moshinsky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhawar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bora, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques-OâHagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">â</span> <span class="NLM_lpage">229</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=226-229&author=H.+Tecleauthor=J.+Shaoauthor=Y.+Liauthor=M.+Kotheauthor=S.+Kazmirskiauthor=J.+Penzottiauthor=Y.-H.+Dingauthor=J.+Ohrenauthor=D.+Moshinskyauthor=R.+Coliauthor=N.+Jhawarauthor=E.+Boraauthor=S.+Jacques-O%E2%80%99Haganauthor=J.+Wu&title=Beyond+the+MEK-pocket%3A+Can+current+MEK+kinase+inhibitors+be+utilized+to+synthesize+novel+type+III+NCKIs%3F+Does+the+MEK-pocket+exist+in+kinases+other+than+MEK%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKazmirski%26aufirst%3DS.%26aulast%3DPenzotti%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DY.-H.%26aulast%3DOhren%26aufirst%3DJ.%26aulast%3DMoshinsky%26aufirst%3DD.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DJhawar%26aufirst%3DN.%26aulast%3DBora%26aufirst%3DE.%26aulast%3DJacques-O%25E2%2580%2599Hagan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DBeyond%2520the%2520MEK-pocket%253A%2520Can%2520current%2520MEK%2520kinase%2520inhibitors%2520be%2520utilized%2520to%2520synthesize%2520novel%2520type%2520III%2520NCKIs%253F%2520Does%2520the%2520MEK-pocket%2520exist%2520in%2520kinases%2520other%2520than%2520MEK%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D226%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Trujillo, J. I.</span><span> </span><span class="NLM_article-title">MEK Inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1045</span><span class="NLM_x">â</span> <span class="NLM_lpage">1069</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1517%2F13543776.2011.577068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=21548849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns12ms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1045-1069&issue=7&author=J.+I.+Trujillo&title=MEK+Inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibitors: a patent review 2008 - 2010</span></div><div class="casAuthors">Trujillo, John I.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1045-1069</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MAPK/extracellular signal-regulated kinase (MEK) inhibitors target the Ras/Raf/MEK/ERK signaling pathway, which is important in cell growth, differentiation and development.  The pathway has been implicated in the progression of a variety of diseases, in particular cancer, as well as in immune and inflammatory diseases such as rheumatoid arthritis, organ transplant rejection, septic shock, asthma and viral infection.  Areas covered: A comprehensive review of the patent literature (2008 - 2010) covering MEK inhibitors and combinations thereof is provided in this paper.  Expert opinion: The first MEK inhibitor was described in the literature in 1995, and several companies are still active in the research and development of MEK inhibitors for various disease states.  The emerging role of MEK inhibitors in disease has prompted further investigations of this important target.  The combination of MEK inhibitors with other agents/therapies in the treatment of diseases, particularly cancer, is a key development in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Dlhu0B2Us7Vg90H21EOLACvtfcHk0lj5k9LUA60A5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns12ms7Y%253D&md5=bd41140872c9005e24c4cf5597a4493d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.577068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.577068%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26atitle%3DMEK%2520Inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26issue%3D7%26spage%3D1045%26epage%3D1069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Politzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Concha, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. S.</span><span> </span><span class="NLM_article-title">An overview of halogen bonding</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1007%2Fs00894-006-0154-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17013631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFantL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=305-311&author=P.+Politzerauthor=P.+Laneauthor=M.+C.+Conchaauthor=Y.+Maauthor=J.+S.+Murray&title=An+overview+of+halogen+bonding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of halogen bonding</span></div><div class="casAuthors">Politzer, Peter; Lane, Pat; Concha, Monica C.; Ma, Yuguang; Murray, Jane S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-311</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Halogen bonding (XB) is a type of noncovalent interaction between a halogen atom X in one mol. and a neg. site in another.  X can be chlorine, bromine or iodine.  The strength of the interaction increases in the order Cl < Br < I.  After a brief review of exptl. evidence relating to halogen bonding, we present an explanation for its occurrence in terms of a region of pos. electrostatic potential that is present on the outermost portions of some covalently-bonded halogen atoms.  The existence and magnitude of this pos. region, which we call the Ï-hole, depends upon the relative electron-attracting powers of X and the remainder of its mol., as well as the degree of sp hybridization of the s unshared electrons of X.  The high electronegativity of fluorine and its tendency to undergo significant sp hybridization account for its failure to halogen bond.  Some computed XB interaction energies are presented and discussed.  Mention is also made of the importance of halogen bonding in biol. systems and processes, and in crystal engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4jkNxRc08s7Vg90H21EOLACvtfcHk0lj5k9LUA60A5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFantL0%253D&md5=8d75bb2014ec661e2b1b657fff41e821</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs00894-006-0154-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-006-0154-7%26sid%3Dliteratum%253Aachs%26aulast%3DPolitzer%26aufirst%3DP.%26aulast%3DLane%26aufirst%3DP.%26aulast%3DConcha%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520overview%2520of%2520halogen%2520bonding%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2007%26volume%3D13%26spage%3D305%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Voth, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. S.</span><span> </span><span class="NLM_article-title">The role of halogen bonding in inhibitor recognition and binding by protein kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1336</span><span class="NLM_x">â</span> <span class="NLM_lpage">1348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.2174%2F156802607781696846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=17692024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1336-1348&author=A.+R.+Vothauthor=P.+S.+Ho&title=The+role+of+halogen+bonding+in+inhibitor+recognition+and+binding+by+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The role of halogen bonding in inhibitor recognition and binding by protein kinases</span></div><div class="casAuthors">Voth, Andrea Regier; Ho, P. Shing</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1336-1348</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Halogen bonds are short-range mol. interactions that are analogous to classical hydrogen bonds, except that a polarized halogen replaces the hydrogen as the acid in the Lewis acid/base pair.  Such interactions occur regularly in the structures of many ligand-protein complexes, but have only recently been recognized in biol. systems as a distinct class with well-defined phys. characteristics.  In this review, we survey twelve single crystal structures of protein kinase complexes with halogenated ligands in order to characterize the role of halogen bonds in conferring specificity and affinity for halogenated inhibitors in this important class of enzymes.  From this survey, we attempt to identify the properties of halogen bonds that can be generally applied to bottom-up strategies for designing inhibitors for this and other enzyme targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0lKs3fgdLV7Vg90H21EOLACvtfcHk0lj5k9LUA60A5w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrJ&md5=da1c1d603db9c2d93682f428198f0515</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156802607781696846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696846%26sid%3Dliteratum%253Aachs%26aulast%3DVoth%26aufirst%3DA.%2BR.%26aulast%3DHo%26aufirst%3DP.%2BS.%26atitle%3DThe%2520role%2520of%2520halogen%2520bonding%2520in%2520inhibitor%2520recognition%2520and%2520binding%2520by%2520protein%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1336%26epage%3D1348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Iverson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, L.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dadson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarten, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quart, B.</span><span> </span><span class="NLM_article-title">RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6839</span><span class="NLM_x">â</span> <span class="NLM_lpage">6847</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6839-6847&author=C.+Iversonauthor=G.+Larsonauthor=C.+Laiauthor=L.-T.+Yehauthor=C.+Dadsonauthor=P.+Weingartenauthor=T.+Applebyauthor=T.+Voauthor=A.+Madernaauthor=J.+M.+Vernierauthor=R.+Hamatakeauthor=J.+N.+Minerauthor=B.+Quart&title=RDEA119%2FBAY+869766%3A+A+potent%2C+selective%2C+allosteric+inhibitor+of+MEK1%2F2+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIverson%26aufirst%3DC.%26aulast%3DLarson%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DYeh%26aufirst%3DL.-T.%26aulast%3DDadson%26aufirst%3DC.%26aulast%3DWeingarten%26aufirst%3DP.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DVo%26aufirst%3DT.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26aulast%3DQuart%26aufirst%3DB.%26atitle%3DRDEA119%252FBAY%2520869766%253A%2520A%2520potent%252C%2520selective%252C%2520allosteric%2520inhibitor%2520of%2520MEK1%252F2%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6839%26epage%3D6847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Laurence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Questel, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renault, E.</span><span> </span><span class="NLM_article-title">The p<i>K</i><sub>BHX</sub> database: toward a better understanding of hydrogen-bond basicity for medicinal chemists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4073</span><span class="NLM_x">â</span> <span class="NLM_lpage">4086</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.+Y.+Le+Questelauthor=E.+Renault&title=The+pKBHX+database%3A+toward+a+better+understanding+of+hydrogen-bond+basicity+for+medicinal+chemists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0lgyBL8v3IgA1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.%2BY.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pKBHX%2520database%253A%2520toward%2520a%2520better%2520understanding%2520of%2520hydrogen-bond%2520basicity%2520for%2520medicinal%2520chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wallace, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarski, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otten, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hingorani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, K.</span><span> </span><span class="NLM_article-title">Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050834y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=441-444&author=E.+M.+Wallaceauthor=J.+Lyssikatosauthor=J.+F.+Blakeauthor=J.+Seoauthor=H.+W.+Yangauthor=T.+C.+Yehauthor=M.+Perrierauthor=H.+Jarskiauthor=V.+Marshauthor=G.+Pochauthor=M.+G.+Livingstonauthor=J.+Ottenauthor=G.+Hingoraniauthor=R.+Woessnerauthor=P.+Leeauthor=J.+Winklerauthor=K.+Koch&title=Potent+and+selective+mitogen-activated+protein+kinase+kinase+%28MEK%29+1%2C2+inhibitors.+1.+4-%284-Bromo-2-fluorophenylamino%29-1-methylpyridin-2%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm050834y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050834y%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%2BW.%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DPerrier%26aufirst%3DM.%26aulast%3DJarski%26aufirst%3DH.%26aulast%3DMarsh%26aufirst%3DV.%26aulast%3DPoch%26aufirst%3DG.%26aulast%3DLivingston%26aufirst%3DM.%2BG.%26aulast%3DOtten%26aufirst%3DJ.%26aulast%3DHingorani%26aufirst%3DG.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DKoch%26aufirst%3DK.%26atitle%3DPotent%2520and%2520selective%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520%2528MEK%2529%25201%252C2%2520inhibitors.%25201.%25204-%25284-Bromo-2-fluorophenylamino%2529-1-methylpyridin-2%25281H%2529-ones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D441%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Price, S.; Williams, K.; Savy, P. P.; Dyke, H. J.; Montana, J. G.; Stanley, M. S.; Bao, L.</span><span> </span><span class="NLM_article-title">Aza-benzofuranyl compounds and methods of use</span>. Patent WO2008024725,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Price&author=K.+Williams&author=P.+P.+Savy&author=H.+J.+Dyke&author=J.+G.+Montana&author=M.+S.+Stanley&author=L.+Bao&title=Aza-benzofuranyl+compounds+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DS.%26atitle%3DAza-benzofuranyl%2520compounds%2520and%2520methods%2520of%2520use%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robarge, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span> </span><span class="NLM_article-title">Preclinical disposition and pharmacokineticsâpharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">751</span><span class="NLM_x">â</span> <span class="NLM_lpage">762</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=751-762&author=E.+F.+Chooauthor=M.+Belvinauthor=J.+Chanauthor=K.+Hoeflichauthor=C.+Orrauthor=K.+Robargeauthor=X.+Yangauthor=M.+Zakauthor=J.+Boggs&title=Preclinical+disposition+and+pharmacokinetics%E2%80%93pharmacodynamic+modeling+of+biomarker+response+and+tumour+growth+inhibition+in+xenograft+mouse+models+of+G-573%2C+a+MEK+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DHoeflich%26aufirst%3DK.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DRobarge%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DBoggs%26aufirst%3DJ.%26atitle%3DPreclinical%2520disposition%2520and%2520pharmacokinetics%25E2%2580%2593pharmacodynamic%2520modeling%2520of%2520biomarker%2520response%2520and%2520tumour%2520growth%2520inhibition%2520in%2520xenograft%2520mouse%2520models%2520of%2520G-573%252C%2520a%2520MEK%2520inhibitor%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D11%26spage%3D751%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandretto, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, G. W.</span><span> </span><span class="NLM_article-title">Kinase inhibitors and the case for CH...O hydrogen bonds in proteinâligand binding</span> <span class="citation_source-journal">Proteins</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">567</span><span class="NLM_x">â</span> <span class="NLM_lpage">576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2002&pages=567-576&author=A.+C.+Pierceauthor=K.+L.+Sandrettoauthor=G.+W.+Bemis&title=Kinase+inhibitors+and+the+case+for+CH...O+hydrogen+bonds+in+protein%E2%80%93ligand+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DSandretto%26aufirst%3DK.%2BL.%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DKinase%2520inhibitors%2520and%2520the%2520case%2520for%2520CH...O%2520hydrogen%2520bonds%2520in%2520protein%25E2%2580%2593ligand%2520binding%26jtitle%3DProteins%26date%3D2002%26volume%3D49%26spage%3D567%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Toth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, S. G..</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probst, G.</span><span> </span><span class="NLM_article-title">The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3476</span><span class="NLM_x">â</span> <span class="NLM_lpage">3493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.2174%2F138161207782794284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=18220785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3476-3493&author=G.+Tothauthor=S.+G..+Bowersauthor=A.+P.+Truongauthor=G.+Probst&title=The+role+and+significance+of+unconventional+hydrogen+bonds+in+small+molecule+recognition+by+biological+receptors+of+pharmaceutical+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance</span></div><div class="casAuthors">Toth, Gergely; Bowers, Simeon G.; Truong, Anh P.; Probst, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3476-3493</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery and optimization of nonbonded interactions, such as van der Waals interactions, hydrogen bonds, salt bridges and the hydrophobic effect, between small mol. ligands and their receptors is one of the main challenges in rational drug discovery.  As the theory of mol. interactions advances more evidence accumulates that nonbonded interactions, such as unconventional hydrogen bonds (X-HÂ·Â·Â·Y interactions, where X can be either C, N or O atom and Y can be either an arom. ring system, O or F atom), contribute to ligand recognition by biol. receptors.  This review provides an overview of unconventional hydrogen bonds between ligands and their receptors of pharmaceutical relevance by dissecting their structure activity relationships and 3D structural elements.  Gaining an understanding of the energetic and the structural properties of unconventional hydrogen bonds in ligand-receptor interactions leads us to the elucidation of their practical significance.  Ultimately, this enables us to consciously apply these interactions in hit and lead optimization in rational structure based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOm79X4bmpLrVg90H21EOLACvtfcHk0lgyBL8v3IgA1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrs73E&md5=543b57cfacc29b0389740eea1ab60b73</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138161207782794284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207782794284%26sid%3Dliteratum%253Aachs%26aulast%3DToth%26aufirst%3DG.%26aulast%3DBowers%26aufirst%3DS.%2BG..%26aulast%3DTruong%26aufirst%3DA.%2BP.%26aulast%3DProbst%26aufirst%3DG.%26atitle%3DThe%2520role%2520and%2520significance%2520of%2520unconventional%2520hydrogen%2520bonds%2520in%2520small%2520molecule%2520recognition%2520by%2520biological%2520receptors%2520of%2520pharmaceutical%2520relevance%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D3476%26epage%3D3493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Fink, D. M.; Strupczewski, J. T.</span><span> </span><span class="NLM_article-title">Process and intermediates for the preparation of 6-fluorobenzoisothiazoles</span>. Can. Pat. Appl. CA 2076556,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=D.+M.+Fink&author=J.+T.+Strupczewski&title=Process+and+intermediates+for+the+preparation+of+6-fluorobenzoisothiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFink%26aufirst%3DD.%2BM.%26atitle%3DProcess%2520and%2520intermediates%2520for%2520the%2520preparation%2520of%25206-fluorobenzoisothiazoles%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">â</span> <span class="NLM_lpage">1749</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Ã in nearly half of the cases and are greater than 2 Ã in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lgA3EuMk-0ATA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray Diffraction Data Collected in Oscillation Mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">â</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm2017094&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+Diffraction+Data+Collected+in+Oscillation+Mode"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (Ï2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Ã unit cell to rotavirus of 700 Ã diam. crystd. in 700 Ã 1000 Ã 1400 Ã cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lgA3EuMk-0ATA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520Diffraction%2520Data%2520Collected%2520in%2520Oscillation%2520Mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography Collaborative Computational Project, Number 4</span>.  <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">D50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">763</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CCP4+suite%3A+programs+for+protein+crystallography+Collaborative+Computational+Project%2C+Number+4.+Acta+Crystallogr.%2C+Sect.+D%3A+Biol.+Crystallogr.+1994%2C+D50%2C+760%E2%80%93763%3B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%2520Collaborative%2520Computational%2520Project%252C%2520Number%25204%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3DD50%26spage%3D760%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_contrib-group">Vagin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teplyakov, A.</span><span> </span><span class="NLM_article-title">MOLREP: an Automated Program for Molecular Replacement</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">â</span> <span class="NLM_lpage">1025</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm2017094&amp;key=10.1107%2FS0021889897006766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm2017094&amp;key=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1997&pages=1022-1025&author=A.+Vaginauthor=A.+Teplyakov&title=MOLREP%3A+an+Automated+Program+for+Molecular+Replacement"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">MOLREP: an automated program for molecular replacement</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1022-1025</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement which uses effective new approaches in data processing and rotational and translational searching.  These include an automatic choice of all parameters, scaling by Patterson origin peaks and soft resoln. cutoff.  One of the cornerstones of the program is an original full-symmetry translation function combined with a packing function.  Information from the model already placed in the cell is incorporated in both translation and packing functions.  A no. of tests using exptl. data proved the ability of the program to find the correct soln. in difficult cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkGXdZ-nTKxLVg90H21EOLACvtfcHk0ljJhL4Fkr-Jqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhslehu7Y%253D&md5=96af64aedd8a8f018c3c18b57a6b4b21</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1107%2FS0021889897006766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889897006766%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMOLREP%253A%2520an%2520Automated%2520Program%2520for%2520Molecular%2520Replacement%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1997%26volume%3D30%26spage%3D1022%26epage%3D1025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V04" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V04','PDB','3V04'); return false;">PDB: 3V04</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VO1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VO1','PDB','3VO1'); return false;">PDB: 3VO1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1S9J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1S9J','PDB','1S9J'); return false;">PDB: 1S9J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V01" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V01','PDB','3V01'); return false;">PDB: 3V01</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a href="/doi/suppl/10.1021/jm2017094">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63014"></div></div></div></div></div><hr /></hr><p class="last">Methods and further results for the in vivo pharmacodynamic and efficacy studies involving <b>1</b>; experimental procedures for the preparation of compounds <b>12</b>â<b>17</b>; NMR spectra for <b>1</b> and <b>19</b>; data collection and refinement statistics for complexes of <b>3</b> and <b>1</b> with MEK1; kinase panel data for <b>1</b>; rat in vivo metabolite identification for <b>1</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm2017094/suppl_file/jm2017094_si_001.pdf">jm2017094_si_001.pdf (188.97 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm2017094&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm2017094%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-10%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm2017094" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995a7bee453cb2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
